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Abstract 
Ischaemic heart disease is the most common cause of mortality in the 
western hemisphere and it is rapidly becoming the leading cause of death 
globally. Moreover, therapeutic interventions by cardiologists and cardiac 
surgeons frequently subject the heart to acute I/R injury, which in itself can 
cause mortality.  
Recent investigations of adult stem cells have primarily focused on their 
regenerative potential for chronic ischaemic heart disease. In this thesis, I 
have investigated the hypothesis that adult bone marrow derived stem cells 
are cardioprotective in acute regional myocardial I/R injury. In a rat model 
of left anterior descending coronary artery (LAD) reversible occlusion and 
reperfusion, I demonstrate that an intravenous bolus of adult bone marrow 
derived (1) bone marrow mononuclear (BMNNC) and (2) mesenchymal 
stem cells (MSC) upon reperfusion can attenuate infarct size. This effect is 
comparable to ischaemic preconditioning (IPC), which is the gold standard 
for cardioprotection.  
Next, I demonstrated the mechanisms for adult stem cell 
cardioprotection are principally anti-apoptotic and depend upon stem cell 
secreted factors to (1) activate phosphatidylinositide 3-kinase (PI3)/Akt cell 
survival kinase-signaling pathway (2) inhibit glycogen synthase kinase-3β  
(3) inhibit p38MAPK (4) inhibit nuclear translocation of p65NF-κB. 
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Proteomic analysis of myocardium subjected to I/R and treated with either 
BMMNC or BMMNC derived supernatant (BMS) upon reperfusion 
demonstrated higher expression of  a whole host of pro-survival proteins. 
These were notably (1) 14-3-3-ε protein (2) anti-oxidant peroxiredoxin-6 (3) 
heat shock protein (HSP) αB-crystallin, HSP72, HSP tumour necrosis factor 
receptor-1 associated protein, and HSP ischaemia responsive protein-94 (4) 
glycolytic protein glyceraldehyde-3-phosphate dehydrogenase (5) 
mitochondrial aconitase and mitochondrial voltage-dependent anion-
selective channel protein-1.  
Thereafter, I investigated the mobilization of endogenous bone marrow 
stem cells and trafficking to the ischaemic myocardium by stromal cell 
derived factor-1 (SDF-1) /chemokine, receptor type 4 (CXCR4) signaling. I 
demonstrate high up-regulated expression of CXCR4 and CD26 in 
BMMNC following IPC, which might have a role in IPC-mediated 
cardioprotection. Finally, and in concordance with this finding I 
demonstrate that both IPC and an exogenous MSC bolus upon reperfusion 
can synergize to abolish acute myocardial I/R injury. 
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Chapter 1 
General Introduction 
1.1 Ischaemic Heart Disease 
The heart is a muscular pump that sustains an adequate perfusion of 
blood to itself, the brain, and all other corporeal tissues. The heart exerts its 
function until death of the organism with the same or lesser number of cells 
than those present from birth (Chien 2004). Heart muscle, or myocardium, 
may lose a significant number of functional cells due to ischaemia. 
Ischaemia is a state of blood deprivation with a consequent denial of oxygen 
and other metabolic substrates. Myocardial ischaemia leads to cellular 
death, myocardial dysfunction and eventually death of the organism. 
Ischaemic heart disease is the leading cause of death in the West (Rosamond 
et al., 2007). With the rapid economic development of the east, ischaemic 
heart disease is set to become the leading cause of death globally by 2020 
(He et al., 2005). Each year, 19 million people worldwide experience the 
morbidity and mortality of an ischaemic myocardial episode (Naghavi et al., 
2003). Ischaemic heart disease is also an economic burden, for example in 
the United Kingdom; the National Health Service spends £1.7 billion 
annually on ischaemic heart disease patients. United States, in comparison, 
spend $186 billion annually on ischaemic heart disease (Cohn et al., 1997). 
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The loss of human life and the costs to the global economy continues to 
drive the tremendous research effort to discover novel strategies to protect 
against ischaemic heart disease. 
1.1.1 Pathophysiology of Myocardial Ischaemia  
The myocardium is a syncytium of cells, or cardiomyocytes, which 
function in electro-mechanical synchrony and form 75% of the contractile 
mass of the heart (Brilla et al., 1991; Zak 1974). This syncytium of 
cardiomyocytes are maintained in an extracellular matrix (ECM), which is 
necessary  to maintain the functional integrity and consists of an intricate 
network of type 1 and type 3 collagenous fibres produced by numerous 
myofibroblasts (Zak 1974; Weber 1997). Around 60% of each 
cardiomyocyte consists of contractile proteins invested with a dense array of 
mitochondria occupying approximately 20% of the cardiomyocyte volume. 
This high ratio of myofibrils to mitochondria are necessary to generate  the 
high levels of intra-cardiomyocyte adenosine 3´, 5´-triphosphate (ATP) by 
oxidative phosphorylation (Schaper et al., 1985). Thus in comparison to 
other bodily organs, myocardial oxygen consumption is the highest per mass 
per minute; i.e. 10ml oxygen per minute per 100mg of myocardium. 
Consequently, more than 75% of the oxygen delivered to the heart is subject 
to immediate extraction from the myocardial coronary blood flow. This 
limited  physiological reserve mandates significant increases in coronary 
blood flow to ensure a balance in oxygen demand and supply is met 
especially during  states of increased myocardial contractility (Camici et al., 
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1996; Feigl 1983; Klocke 1976). It therefore also follows that the 
myocardium poorly tolerates luminal coronary arterial stenoses that limit 
perfusion and subject the myocardium to profound hypoxia even at rest. 
Such coronary artery perfusion defects are the principal cause of myocardial 
ischaemia and associated myocardial dysfunction or mortality.  
During the pathophysiological state of myocardial ischaemia,  
glucose becomes the primary substrate for anaerobic production of ATP, but 
this glycolytic process has a significantly lower yield of ATP than that 
produced by fatty acid oxidation  (Camici et al., 1996; Oliver et al., 1994; 
Rouslin et al., 1990). Persistent glycolysis leads to an accumulation of 
pyruvate and nicotinamide adenine dinucleotide, which inhibits pyruvate 
dehydrogenase activity and prevents pyruvate entry into the mitochondria 
(Salem et al., 2002). Accumulating pyruvate conversion to lactic acid leads 
to profound acidosis (Zemgulis et al., 2001). Inevitably, glycolysis cannot 
generate sufficient ATP for myofibril contractility and maintenance of the 
important ion exchange mechanisms such as sodium/potassium ion pump 
activity (Na+/K+/ATPase), which is necessary for normal myocyte 
membrane polarity. Thus, continued dependence upon anaerobic 
metabolism rapidly leads to myocardial hypokinesis and accumulation of 
intra-myocyte Na+. Intra-cardiomyocyte acidosis causes further Na+ 
accumulation by increased sodium/hydrogen ion exchanger-1 (NHE-1) 
activity (Karmazyn et al., 1999). Overload of Na+ switches the 
sodium/calcium exchanger (NCX) into reverse mode to lower intra-myocyte 
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Na+ but at the expense of increased intracellular Ca2+. The combined Na+ 
and Ca2+ overload leads to osmotic cellular swelling, loss in cell membrane 
integrity, and necrotic cell death (Murphy et al., 2008; Pedersen 2006). 
Ischaemic cell death is primarily by necrosis, as it proceeds in the absence 
of ATP, and contrasts cell death by dependence on ATP i.e. apoptosis. 
Consequently, 70% of the myocardium will undergo necrosis following 3 h 
of continuous ischaemia. Termination of myocardial ischaemia by 
restoration of an adequate coronary blood flow is termed reperfusion and 
this is an essential first step in limiting injury to the ischaemic myocardium.   
1.1.2 Pathophysiology of Myocardial Reperfusion 
Reperfusion of an ischaemic myocardium limits necrotic injury and 
attenuates acute myocardial infarction (AMI) by 40% (Reimer et al., 1977). 
Reperfusion, however, can propagate tissue injury beyond that sustained by 
ischaemia alone (Jennings et al., 1960; Braunwald et al., 1985).  This 
paradoxical effect of reperfusion following ischaemia is widely termed 
reperfusion injury. At the onset of reperfusion, there is a rapid production of 
reactive oxygen species (ROS), correction of intra-cellular acidaemia, but 
this is at the expense of further Na+ overload, Ca2+ overload, and 
consequential depression of myocardial contractility or stunning. Thus, 
during prolonged ischaemia over activity of NHE-1 leads to Na+ overload 
and secondarily to Ca2+ overload due to reverse activity of the NCX. ROS 
can further increase NHE-1 activity by H2O2 mediated phosphorylation by 
mitogen activated protein kinases (MAPK), which include p38, c-jun, NH2-
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terminal kinase (JNK) and extracellular signal-regulated kinases 1/2 (Sabri 
et al., 1998; Wei et al., 2001; (Snabaitis et al., 2002); Moor et al., 2001).  
NHE-1 activity is at its peak during the initial period of reperfusion and 
results in a greatly increased intracellular Na+ concentration, which affects 
the direction of NCX. NCX activity is important for the removal of 
intracellular Ca2+ from the cardiomyocyte, but NCX is sensitive to sub-
sarcolemmal Na+. Thus, the increased intracellular Na+ causes a reverse 
mode NCX action leading to Ca2+ influx into the cardiomyocyte. ROS can 
also directly increase NCX activity as shown by exposure of 
cardiomyocytes to H2O2 (Goldhaber 1996). Accumulating cytosolic Ca2+ 
leads to increased mitochondrial Ca2+ and causes mitochondrial swelling 
with eventual mitochondrial outer membrane disruption (Shen et al., 1972). 
Loss of mitochondrial outer membrane integrity and leakage of 
mitochondrial pro-apoptotic factors triggers apoptotic cell death.   
An important combined effect of ROS and mitochondrial calcium 
overload during reperfusion leads to the opening of a non-specific inner 
mitochondrial membrane pore called the mitochondrial permeability 
transitional pore (MPTP). Opening of MPTP is detectable 2 to 3 minutes 
after the onset of myocardial reperfusion but not during ischaemia 
(Halestrap et al., 2004). MPTP opening leads to uncontrolled proton entry 
into the mitochondrial matrix and loss of the inner mitochondrial membrane 
potential or proton motive force, which is essential for oxidative 
phosphorylation. This not only decelerates mitochondrial ATP production 
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but also accelerates hydrolysis of all cellular ATP to cause a rapid decline in 
the total cellular ATP levels (Halestrap et al., 2004). The primary trigger for 
MPTP opening is increase in matrix calcium (Crompton et al., 1987), and 
sensitivity to opening is further increased by mitochondrial ROS, phosphate, 
and mitochodrial membrane depolarization (Halestrap 2009). The 
maintenance of MPTP closure is by the normally high levels of ATP, ADP, 
Mg2+, and H+ within the mitochondrial matrix. The molecular components 
of MPTP have not been entirely characterised, however, the discovery of 
Cyclophilin D (CypD) as a facilitator of MPTP opening in the presence of 
calcium and phosphate was a milestone in the understanding of the MPTP 
mechanism (Crompton et al., 1988). States of calcium overload lead to 
increased CypD binding to the mitochondrial phosphate carrier (PiC) to 
enable MPTP activation. This facilitating role of CypD during calcium 
overload can be desensitized by the sub-micromolar concentrations of the 
immunosuppressant Cyclosporin A (Leung et al., 2008b).  The key MPTP 
pore forming protein(s) remain elusive to date.  Adenine nucleotide 
translocase (ANT) may be an MPTP pore forming protein as it binds to ATP 
or its deoxyribose analogues to reduce the calcium sensitivity of MPTP 
opening (Halestrap et al., 1997).  Oxidative stress or the “c” conformation 
caused by carboxyatractyloside prevents the binding of ANT to adenine 
nucleotides (Halestrap et al., 1997). Data that is more recent however 
suggests genetic ablation of ANT significantly reduces MPTP opening 
sensitivity to calcium but does not abolish it (Kokoszka et al., 2004 4551). 
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This suggests that ANT may not be the essential protein for MPTP pore 
formation. Other data points to PiC as being a possible MPTP pore forming 
protein (Leung et al., 2008a). There are however, other proteins that might 
have a role in the formation of MPTP pore and of which a 32kDa protein 
identified as voltage dependent anion channel isoform-1 (VDAC-1) is 
supported by the strongest evidence (Cesura et al., 2003; Crompton et al., 
1998).     
Reperfusion of the ischaemic myocardium results in significant 
depression in myocardial function (Braunwald et al., 1982; Heyndrickx et 
al., 1975). During reperfusion the myocardial myofilaments have decreased 
sensitivity to Ca2+. The exact mechanism for this is not yet resolved. 
Overload of Ca2+ may cause proteolysis of the myofilament regulatory 
proteins such as Troponin I (Gao et al., 1996; Mcdonough et al., 1999; Van 
Eyk et al., 1998). Other studies argue against this suggested mechanism 
(Feng et al., 2001; Kim et al., 2001; Thomas et al., 1999). Overload of Ca2+ 
and MAPK activation, particularly overexpression of JNK and p38 MAPK, 
can also lead to myofibrillar disassembly.  
Reperfusion of the ischaemic myocardium is associated with an 
exponential production of ROS, which also contributes directly to the 
persistent myocardial dysfunction (Bolli et al., 1988). ROS may directly 
decrease contractility by decreased myofibrillar ATPase, decreasing creatine 
kinase activity, stimulating myosin phosphatase, or by metabolic depletion 
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of ATP (Hein et al., 1995; Shattock 1997).  ROS are bio-reactive free 
radicals including superoxide anion radical (O2-.), hydrogen peroxide 
(H2O2), hydroxyl radical (·OH), lipid peroxide (ROO·), and peroxynitrite 
(ONOO-). The reactions that generate ROS have been summarised in table 
1.1.2.1. Electron paramagnetic spin resonance spectroscopy has 
demonstrated that although ROS are generated during ischaemia, the 
greatest increase in ROS generation occurs during the initial moments of 
reperfusion (Bolli et al., 1988; Zweier et al., 1987). This explosive burst of 
ROS occurs within minutes of reperfusion and mandates presence of oxygen 
(Zweier et al., 1987). In the ischaemic and reperfusing heart, ROS 
generation is by cardiomyocytes, endothelium and neutrophils. The 
mitochondria are the major intracellular source of ROS, particularly 
complexes 1 and 3 of the electron transport chain (Turrens 2003). ROS have 
profound deleterious effects on the myocardium, which include peroxidation 
of lipids and proteins. Thus, ROS can interfere with the normal functions of 
various intracellular targets including second messenger pathways, L-type 
Ca2+ channels, potassium channels, ion transporters, and contractile proteins 
(Park et al., 1999). Cardiomyocytes’ exposure to O2-. and H2O2 has been 
shown to inhibit active Na+ and Ca2+ pumps and at the same time activate 
NCX (Goldhaber et al., 1994). ROS also reduce myofibrillar ATPase 
activity, which can attenuate the responsiveness to Ca2+ and contributes to 
myocardial stunning(Ventura et al., 1985). Under physiological conditions, 
ROS levels are low due to the mitochondrial antioxidant defence 
 
 
25 
 
mechanisms, which include enzymes such as superoxide dismutase (SOD), 
glutathione peroxidase, and glutathione reductase. Mitochondrial non-
enzymatic anti-oxidants include glutathione and α-tocopherol and coenzyme 
Q.  Antioxidants act by scavenging oxidative species and their precursors.  
However, during I/R the balance between oxidants and antioxidants is 
perturbed, resulting in oxidative stress. Thus, amelioration of ROS by the 
use of scavengers of free radicals such as catalase and superoxide dismutase 
can reduce reperfusion injury (Zweier et al., 1987). In concordance with 
this, the Cambridge Heart Antioxidant Study (CHAOS) trial demonstrated a 
decreased incidence of cardiovascular events in patients with coronary 
disease following treatment with vitamin E (Stephens et al., 1996).   
During I/R excessive ROS exerts many deleterious effects on 
myocardial tissue by reacting with membrane lipids, proteins and nucleic 
acids to alter their physiological function. ROS have been demonstrated to 
induce lipid peroxidation in reperfused hearts (Ambrosio et al., 1991; 
Paradies et al., 2004; Paradies et al., 1999).  This process results in the 
fragmentation of fatty acids and in the formation of lipid peroxidation 
products, the products of which are cytotoxic.  During the massive release 
of ROS upon reperfusion membrane ion channel proteins, that play a key 
role in the homeostasis of cardiomyocytes,  alter their permeability to K+, 
Ca2+ and to Na+.  The activities of ion pumps such as Na+/K+/ATPase and 
sarcolemmal Ca2+/ATPase decreases after the exposure to oxidative stress.  
The ischaemic myocyte has an accumulation of intracellular Ca2+  due to 
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increased activity of reverse mode NCX  and there is a further increase in 
cytosolic Ca2+ upon reperfusion(Meissner et al., 1995). Additonal 
contributors for Ca2+ overload include decreased sarcoplasmic reticulum 
reuptake, decreased Ca2+ extrusion, increased entry from voltage-sensitive 
Ca2+ channels. The Ca2+  overload does not increase myocardial contrctility 
as the oxidative modification of contractile proteins causes myocardial 
stunning and haemodynamic failure.   
In addition to the cell damaging effects of ROS, reperfusion of the 
previously ischaemic heart is also associated with an intense inflammatory 
reaction and the recruitment of leukocytes into the reperfusing myocardium 
(Engler et al., 1986). Engler et al.,, have shown that compared to regional 
ichaemia alone, reperfusion greatly enchanced infiltration of neutrophils 
into the reperfusing myocardium. Neutrophil migration from the circulation 
into the myocardium is via a complex sequence of molecular steps involving 
selectins and integrins, which are a group of cellular adhesion molecules 
that mediate leukocyte adhesion and rolling to the endothelium. Neutrophils 
extravasate by leucocyte integrin (CD11/CD18) interactions with 
endothelial intercellular adhesion molecule-1 (ICAM-1) so permitting 
neutrophil adhesion to the endothelium and subsequent transmigration 
(Entman et al., 1991). Complement fragments such as C5a(Mueller et al., 
2013) and cytokines such as tumour necrosis factor alpha (TNF-), 
interleukin (IL)-1, IL-6 or IL-8 act as chemoattractant factors that stimulate 
neutrophil mediated events following I/R of the heart. Neutrophil 
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stimulation with chemotactic factors (e.g. C5a, IL-8, PAF, f-Met-Leu-Phe) 
and endothelial stimulation by inflammatory cytokines (e.g. IL-1, TNFα, 
endotoxin) significantly augments neutrophil transmigration (Smith et al., 
1989; Smith et al., 1988). Transmigrated neutrophils then bind to 
cardiomyocytes expressing ICAM-1 and thereby inject a burst of NADPH 
oxidase generated ROS and proteolytic enzymes into ischaemic and 
reperfusing myocytes (Entman et al., 1992). These neutrophil mediated 
cytotoxic effects are necessary to remove non-viable cardiomyoctes to 
facilitate repair and remodelling post I/R (Richard et al., 1995; Roberts et 
al., 1976). Subsequent to the acute inflammatory repsonse, adaptive immune 
cells (i.e. monocytes and lymphocytes) are recruited to the reperfusing 
myocardium to enable repair and adverse remodelling (Yan et al., 2013).  
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Table 1.1.2.1: ROS generating reactions 
Reduction of O2 
O2 + e- → ·O2- 
·O2 + e- + 2H+ → H2O2 
·O2- + H2O2 + H+ → O2 + H2O + ·OH 
·OH + e- + H+ → H2O 
Iron-related 
Fe2+ + H2O2 → Fe3+ + ·OH + OH- (Fenton reaction) 
Fe3+ + ·O2- → Fe2+ + O2 
·O2- + H2O2 → O2 + ·OH + OH- (Haber-Weiss 
reaction) 
Lipid peroxidation 
Lipid-H + ·OH → H2O + Lipid· 
Lipid· + O2 → Lipid OO· 
Lipid OO· + Lipid-H → Lipid-OOH + Lipid· 
Lipid· + Lipid· → Lipid-Lipid 
Xanthine-oxidase 
ATP→adenosine→xanthine 
Xanthine + H2O +2O2→uric acid + 2·O2- +2 H+ 
NADPH oxidase NADPH + 2O2→ NAD(P)+ + H+ + 2·O2- 
Peroxynitrite ·NO + ·O2- → ONOO- 
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1.1.3 Protecting the Myocardium from Ischaemia 
Reperfusion Injury  
Protecting the myocardium from ischaemia requires emergent 
restoration of myocardial blood flow and the degree of injury due to 
ischaemia and subsequent reperfusion is critically dependent upon the 
duration of ischaemia. The likelihood of developing cardiac failure and the 
subsequent prognosis has a strong correlation with the infarct size (Page et 
al., 1971; Sobel et al., 1972). Thus, attenuation of ischaemia reperfusion 
(I/R) injury is possible by keeping the ischaemia time to a minimum and 
also by reducing the myocardial demand for oxygen during ischaemia. 
Pharmacological interventions that reduce myocardial oxygen demand 
include β1-adrenoreceptor-blockers, diuretics and vasodilators. In those 
patients with acute coronary artery occlusion, the ischaemia time is kept to a 
minimum by efficient emergency services keeping the time from onset of 
chest pain to thrombolytic therapy or PCI to less than 90 min.  Cardiac 
surgical procedures can reduce the myocardial oxygen consumption by 90% 
using cardioplegic coronary perfusion and topical hypothermia to further 
reduce oxygen consumption by 7% per °C fall in temperature (Bigelow et 
al., 1950; Braimbridge et al., 1977; Buckberg 1979; Melrose et al., 1955; 
Teoh et al., 1986). Reducing myocardial oxygen consumption by 
cardioplegia and hypothermia enables the heart to tolerate significantly long 
periods of global ischaemia during open-heart surgery. These techniques, 
however, cannot completely abolish myocardial oxygen consumption and 
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very long ischaemia times frequently lead to profound myocardial injury, 
multi-organ failure syndrome, and death.  
An innate cardioprotective mechanism that can reliably minimise the 
infarct size due to I/R is called ischaemic preconditioning (IPC) and this 
reported to be the most powerful discovered to date. Myocardial IPC 
follows brief periods of ischaemia of approximately 3-5min duration, which 
can then prevent the significant injury caused by a subsequent prolonged 
period of ischaemia(Jennings et al., 1995; Yellon et al., 1992). IPC was first 
described in a canine model whereby four 5 min cycles of regional 
myocardial ischaemia by left anterior descending coronary artery (LAD) 
reversible occlusion and reperfusion. A subsequent 40 min LAD occlusion 
was associated with significant reductions in infarct size, when compared 
with controls (Murry et al., 1986). This powerful endogenous 
cardioprotection has been also been demonstrated in the rat heart (Liu et al., 
1992b; Liu et al., 1992a), the rabbit  heart (Thornton et al., 1990), the pig 
heart(Schott et al., 1990), and in the human heart (Yellon et al., 1993). The 
mechanism for IPC remains elusive despite the 25 years or so since its 
discovery. Current evidence suggests that IPC activates a complex signaling 
cascade including G-protein coupled receptors(Schultz et al., 1998), Janus 
activated kinase/signal transducers and activators of transcription 
(JAK/STAT) (Bolli et al., 2003),  Src tyrosine kinases (Ping et al., 1999), 
phosphatidylinositol-3 kinase (Tong et al., 2000), ROS (Hausenloy et al., 
2007), protein kinase C-epsilon (Inagaki et al., 2006), glycogen synthase 
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kinase-β inhibition (Tong et al., 2002), and inhibition of the MPTP 
(Juhaszova et al., 2004). IPC as a feasible therapeutic option is only possible 
when I/R is anticipated e.g. cardiopulmonary bypass surgery (Jenkins et al., 
1997; Yellon et al., 1993), and percutaneous transluminal coronary 
angioplasty (Deutsch et al., 1990). But most AMI patients present hours 
after the onset of acute myocardial ischaemia, thus precluding IPC therapy. 
The search for additional myocardial protection strategies has led to 
the publication of over 14000 experimental myocardial protective strategies 
since 1970. Despite these impressive research efforts, translation of these 
putative myocardial protective strategies into actual clinical practice 
remains elusive (Bolli et al., 2004). Further, a significant number of patients 
experience acute myocardial ischaemia out of hospital (Lloyd-Jones et al., 
2010) and most of these patients either do not survive the onset of 
myocardial ischaemia or they present to hospital services many hours or 
even days, following the onset of myocardial ischaemia (Zheng et al., 
2001). Thus, novel strategies to protect the heart against reperfusion injury 
and regenerate a myocardial infarct remain highly sought after. Most 
importantly, there are no current therapies for AMI that target the 
pathogensis of myocardial injury (e.g. ROS production during I/R) or 
facilitate the regeneration of damaged myocardium.   
 
 
 
32 
 
1.2 Stem Cell Therapy Post Acute Myocardial 
Infarction  
Following AMI, cells that originate from within the viable 
myocardium and cells from the circulation invade the infarct zone (Bing 
2001; Cleutjens 1996; Fishbein et al., 1978; Frangogiannis et al., 2002). 
Inflammatory macrophages remove dead cells and fibroblasts proliferate to 
replace the vacated space with dense collagenous scar tissue. Scarring is 
associated with modulation of the ECM and contributes to aneurysmal 
ventricular dilation, diastolic dysfunction, and systolic dysfunction (Jugdutt 
2003). Adverse remodeling has long been thought to be an inevitable and 
irreversible consequence of myocardial injury. This has, however, recently 
been challenged by reports that suggest resident cardiac stem cells 
differentiate into cardiomyocytes to provide regenerative potential (Anversa 
et al., 2006; Beltrami et al., 2003; Nadal-Ginard et al., 2003; Urbanek et al., 
2005). Nevertheless, in reality the endogenous cardiac stem cells fail to 
regenerate a myocardial infarct. The reasons for this are not entirely clear 
and this may simply be due to a significant loss of cardiac stem cells within 
the infarct zone. Hence, an exogenous stem cell resource might redress the 
balance and lead to myocardial repair or regeneration.  
1.2.1 Exogenous Stem Cells 
 Stem cells are unique in that they replicate for self-maintenance and 
provide daughter cells that undergo differentiation for specialized function 
 
 
33 
 
(Till et al., 1961). Stem cells are either embryonic or adult. Embryonic stem 
cells (ESC) constitute the embryonic blastocyst and generate all three germ 
cell layers the ectoderm, mesoderm and endoderm. ESCs are termed 
totipotential because of their potential to generate all tissue cell types (Amit 
et al., 2000; Thomson et al., 1998a; Thomson et al., 1998b). Thus, ESCs 
will differentiate into functional cardiomyocytes (He et al., 2003; Kehat et 
al., 2001; Takahashi et al., 2003; Ventura et al., 2003; Wobus et al., 1997; 
Xu et al., 2002; Xue et al., 2005). In contrast to ESCs, adult stem cells are 
postnatal and restricted in their lineage of differentiation, e.g. 
haematopoietic stem cells will only reconstitute blood cells. More recently, 
this lineage restriction has been challenged and the concept of adult stem 
cell differentiation has evolved to include transdifferentiation; bone marrow 
derived haematopoietic stem cell can differentiate into cells of the brain, 
liver and heart, (Blau et al., 2001; Korbling et al., 2003). Which exogenous 
stem cell type is most appropriate for regenerating the infarcted 
myocardium?  This is still open to debate. 
1.2.1.1 Embryonic Stem Cells and Cardiac Repair 
Embryonic stem cells (ESCs) derive from the inner cell mass of the 
blastocyst, which is complete on day five following fertilization. Isolated 
human ESCs can proliferate indefinitely in the presence of leukaemia 
inhibitory factor or on a feeder layer of mitotically inactivated mouse 
embryonic fibroblasts to provide a stable ESC source (Lebkowski et al., 
2001). ESCs are the ideal cell type for stem cell therapy following 
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myocardial infarction, because they can easily proliferate in culture to 
provide the large numbers of cells necessary and more importantly they can 
be made to differentiate into functional cardiomyocytes both in vitro and in 
vivo (Kehat et al., 2001; Min et al., 2002). Despite the advantages of ESC, 
their clinical employment is restricted by  a number of problems including 
ethical issues, potential for immune rejection, and the potential for intra-
ventricular teratomas (Laflamme et al., 2005).   
1.2.1.2 Adult Stem Cells and Cardiac Repair 
The bone marrow is the primary source for obtaining adult stem 
cells. The most important subpopulation of bone marrow cells used in 
cardiac stem cell therapy is the bone marrow mononuclear cell (BMMNC). 
BMMNC contain mesenchymal stem cells (MSC), haematopoietic stem 
cells (HSC), endothelial progenitor cells (EPC), natural killer cells, T-
lymphocytes, and B-lymphocytes. Alternative sources of adult stem cells 
include adipose tissue, placental tissue, umbilical cord blood and peripheral 
blood.  
The earliest report of an adult stem cell application for cardiac repair 
was by Orlic et al., involving the transplantation of haematopoietic stem 
cells (enriched for c-Kit+ Lin-)  into the  border zone of an ischaemia 
damaged mouse myocardium. The transplanted adult bone marrow derived 
stem cells (c-Kit+ Lin-) could differentiate into all the component cells 
required to produce de novo myocardium, which occupied 68% of the 
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infarct zone 9 days following injection (Orlic et al., 2001).  Interestingly, 
Jackson et al., reported similar myocardial regenerative capacity when a 
side population of haematopoietic stem cells was transplanted into recipient 
bone marrow (Jackson et al., 2001). These initial studies suggested that 
donor adult stem cells migrate in response to signaling from the injured 
heart and then differentiate into a myocardial cell lineage. Further, 
xenogeneic donor cells are also cardioprotective; human adult 
haematopoietic stem cells when injected into rat myocardial infarcts 
transdifferentiated into vascular endothelial cells, prevented cardiomyocyte 
apoptosis, and prevented adverse remodeling (Kocher et al., 2001).  
The initial exciting reports suggesting the regenerative benefits of 
adult bone marrow derived stem cells for myocardial protection have, 
however, been dampened by later reports suggesting that transplanted adult 
bone marrow derived stem cells could not modulate their lineage of 
differentiation for myocardial regeneration (Balsam et al., 2004; Murry et 
al., 2004). The regenerative benefits of adult stem cells were further 
questioned by reports that suggested donor adult bone marrow stem cell 
mechanism of protection might be by the secretion of paracrine factors, 
which could attenuate cardiomyocyte death, following myocardial infarction 
(Gnecchi et al., 2006; Uemura et al., 2006). Nevertheless, autologous 
unfractionated bone marrow mononuclear cells (BMMNC) derived from 
adult bone marrow have been investigated in clinical trials. After AMI, 
patients were revascularized by percutaneous coronary intervention and 
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randomized to receive a single dose of intra coronary BMMNC (Lunde et 
al., 2006; Meyer et al., 2006; Schachinger et al., 2006). Lunde et al., 
reported no improvement in left ventricular ejection fraction (LVEF) at 6 
months; Meyer et al., reported an initial improvement at 6 months, but no 
improvement in LVEF 18 months following intracoronary injection; 
Schachinger et al., reported a 5% improvement in LVEF at 4 months and 
lower mortality from major adverse cardiac events at 1 year. These clinical 
trials did not replicate the improvements in cardiac function suggested by 
the in vivo experimental data. These disparities may be due to differences in 
quality of autologous BMMNC, differences in the time of BMMNC 
injection, differences in the route of injection. In any case, these trials did 
not suggest a regenerative benefit of adult bone marrow stem cell therapy 
and possibly a paracrine effect might have been responsible for the 
improvement in LVEF suggested by Meyer et al., and Schachinger et al. 
1.2.1.3 Mesenchymal stem cells 
 The adult stem cells contained in BMMNC are mainly 
haematopoietic stem cells. The BMMNC content of MSCs (< 0.01%) and 
endothelial progenitor cells (1-2%) is very small. Although a number of 
studies have disputed the regenerative benefits of bone marrow derived stem 
cells in cardiac repair, data from gender mismatched heart transplant and 
bone marrow transplant patients suggest that the adult bone marrow derived 
stem cells do contribute to cardiomyocyte turnover in the heart (Deb et al., 
2003; Quaini et al., 2002). Moreover, Kawada et al. (2004), report that the 
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non-haematopoietic MSC sub-fraction can only differentiate into 
cardiomyocytes (Kawada et al., 2004). This is concordant with the data 
from Pittenger et al. (1999), which suggests that MSCs from various sources 
differentiate into multiple non-haematopoietic lineages including adipose 
tissue, bone, cartilage and cardiomyocytes (Pittenger et al., 1999).  Further, 
bone marrow derived MSCs are able to differentiate into mature functional 
cardiomyocytes both in vitro and in vivo (Makino et al., 1999; Tomita et al., 
1999). 
As well as the regenerative benefits, MSC therapy also imparts non-
regenerative benefits by paracrine-mediated improvement of cardiac 
function, cardiac perfusion and attenuation of apoptosis of the native 
cardiomyocytes (Dai et al., 2005; Tang et al., 2005). Initial clinical studies 
suggest bone marrow-derived MSCs improve cardiac function following 
AMI, but the mechanisms for these benefits are yet to be established (Chen 
et al., 2004). A number of important issues currently prevent the use of 
MSC therapy becoming a realistic clinical option. These include 
optimization of the cell-culture expansion protocols, optimization of 
methods leading to cardiomyocyte differentiation, elimination of 
immunogenic factors in the culture media, identification of the optimal route 
of cell delivery, and identification of the optimal time of cell delivery.  
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1.2.1.4 Endothelial progenitor cells 
 Regeneration of de novo myocardium would necessitate migration 
of bone marrow derived endothelial progenitor cell (EPC) and  their 
myocardial engraftment for neoangiogenesis. This process of 
vasculogenesis was suggested following the discovery of CD34+ peripheral 
blood EPCs (Asahara et al., 1997; Shi et al., 1998). Haematopoietic stem 
cells share a common origin with EPCs by their expression of CD34 or 
CD133 and an endothelial marker such as vascular endothelial growth factor 
receptor 2. Kocher et al., investigated the regenerative benefits of freshly 
isolated CD34+ EPCs adminstered IV in nude rats with myocardial 
ischaemia and found inhibition of cardiomyocyte apoptosis and preservation 
of left ventricular function (Kocher et al., 2001). Similarly, IV injection of 
human EPCs expanded in culture migrated to the ischaemic nude rat 
myocardium to preserve ventricular function and attenuate fibrosis 
(Kawamoto et al., 2001).  The applicability of EPCs in routine clinical 
practice, however, is limited by the scarcity and functional impairment due 
to diabetes, aging, and hypercholesterolaemia (Hill et al., 2003; Vasa et al., 
2001; Werner et al., 2005).  Alternative sources to assure quality and 
quantity of EPC therapy might be from allogeneic cord blood or culture 
expansion from ESCs (Levenberg et al., 2002; Murohara et al., 2000) 
1.2.2 Modalities of Exogenous Stem Cell Delivery 
The efficacy of stem cell therapy for repair of the myocardium is 
reliant upon their successful delivery to the site of injury. Stem cells are 
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delivered by three main ways: (1) IV (systemic or retrograde coronary) (2) 
intra-coronary (3) intra-myocardial. The ideal modality should be safe, 
cheap, easy, widely applicable, targeted and high retention of cells in the 
target area. Prior to stem cell delivery, a process of stem cell mobilization is 
necessary. Following AMI, physiological mechanisms mobilize endogenous 
bone marrow stem cell in humans to attempt cardiac repair (Shintani et al., 
2001). The MAGIC trial used granulocyte colony stimulating factor (G-
CSF) to increase endogenous bone marrow stem cell mobilization prior to 
harvest and delivery (Kang et al., 2004). Most exogenous stem cells 
delivery methods usually involve an invasive clinical procedure to harvest 
the cells prior to delivery, e.g. bone marrow aspiration.  
The advantages of systemic IV stem cell delivery include simplicity, 
low cost, minimally invasive, and rapid donor stem cell migration down a 
chemokine gradient to target the ischaemic myocardium (Lew 2004). This 
cell delivery technique is critically reliant upon the chemokine signaling 
between the ischaemic myocardium and the peripheral circulation. Thus, 
optimal time of delivery by the IV route would be within 2 days of the AMI 
(Barbash et al., 2003). A major drawback of systemic IV is the low 
retention of cells within the zone of injury (Aicher et al., 2003; Barbash et 
al., 2003). Thus, current literature suggests that the systemic IV route of 
stem cell delivery following AMI would not lead to significant regenerative 
benefit.  There is however, no data to suggest that systemic IV injection of 
cells would not lead to a higher cell engraftment in the infarct zone if the 
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injection of cells were earlier than 24 h from the onset of ischaemia or 
reperfusion. Further, there is also no evidence that a particular threshold of 
cellular engraftment is necessary before any regenerative benefit is evident. 
The retrograde coronary venous cell delivery is another 
percutaneous modality of stem cell delivery and has the advantages of 
increased contact time to enhance binding and myocardial concentration 
(Murad-Netto et al., 2004; Von Degenfeld et al., 2003). This technique of 
cell delivery is expensive and not widely available; it would require a 
cardiac catheter suite, X-ray imaging, and operator expertise. Further, the 
use of the coronary venous system for the delivery of cardioplegia during 
cardiac surgery suggests that the right ventricle cannot be adequately 
protected  (Stirling et al., 1989).  
The intracoronary infusion also directly targets the myocardium and it is 
the most common method to clinically to deliver stem cells 4 days or more 
following an acute myocardial infarct (Lunde et al., 2006; Meyer et al., 
2006; Schachinger et al., 2006). This route of cell delivery is widely 
available and uses the same technique for coronary angioplasty in the 
cardiac catheter suite. Thus, the stem cells target the culprit arterial territory 
and stopping the coronary blood flow for 2-4 minutes increases the homing 
time of cell injection. Stem cell homing is further increased by taking 
advantage of the up-regulated homing cytokines and adhesion molecules 
caused by the acute pathology. Despite this highly targeted approach to 
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deliver cells, the efficiency of cellular engraftment is still very poor 
following AMI (Hofmann et al., 2005). Further, the injection of large cells 
such as MSCs could occlude the coronary microcirculation. Vulliet et al., 
report the occurrence of micro infarctions when healthy dogs received MSC 
via the intracoronary route (Vulliet et al., 2004). Furthermore, the evidence 
base that suggests that intracoronary cell delivery is better than other routes 
for safety and efficacy is by no means strong. In the presence of 
extensive/occlusive coronary artery disease and numerous previous 
coronary interventions, this approach limits cell delivery. 
  Intramyocardial cell delivery is the preferred route of cell delivery 
in patients with chronic total occlusion or in permanent coronary ligation 
experimental models. It would also be logical to deliver larger cells such as 
skeletal myoblasts and MSCs intramuscularly to prevent microvascular 
plugging and micro infarctions following cell delivery (Vulliet et al., 2004). 
Intramyocardial cell delivery can be via transepicardial, transendocardial, or 
transcoronary sinus. The transepicardial injection of the myocardium is the 
most invasive technique and requires a median sternotomy. Hence, this 
route is for patients undergoing surgical cardiac procedures, e.g. coronary 
artery bypass grafting. Despite the invasiveness and the associated 
morbidity, it does have a proven safety record (Orlic et al., 2001; Silva et 
al., 2005; Stamm et al., 2003). The surgeon has to make a prior visual 
inspection of the myocardium to ensure optimal targeting of the cell 
injection. However, this technique will not allow inspection of the inter-
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ventricular septum without either a right or left ventriculotomy. On the other 
hand, transendocardial delivery by percutaneous transfemoral insertion of 
the injection catheter avoids the morbidity of a median sternotomy. A more 
accurate targeting of cell delivery is possible by creating electromechanical 
maps of the endocardium to identify viable and non-viable myocardium 
(Sarmento-Leite et al., 2003). The safety profile of this mode of cell 
delivery is excellent in both humans and animals (Fuchs et al., 2001; Perin 
et al., 2003). Transendocardial stem cell delivery in the AMI setting is yet to 
be fully assessed. Trancoronary sinus injection requires the placement of the 
injection catheter into the coronary sinus via a percutaneous transfemoral 
approach. This technique relies on intravascular ultrasound guided cell 
delivery and it has been shown to be feasible and safe (Thompson et al., 
2003). It is however limited because of the need for a high level of operator 
expertise and the challenges of negotiating coronary sinus tortuosity.  The 
delivery of cells by intramuscular injection causes local injury and possibly 
an inflammatory reaction, which might jeopardize the injected cells and 
diminish their engraftment.  Unlike the intravascular delivery modalities, the 
intramuscular injection does not lead to a widespread diffuse engraftment of 
cells, which instead  form islets or cell clusters within the recipient 
myocardium (Leobon et al., 2003; Reinecke et al., 2002). If these injected 
cell clusters were to form de novo myocardium, they may not form 
electromechanical connectivity with the main syncytium, thus have no 
functional contribution, and may become foci of arrhythmias.  
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1.2.3 Stem Cell Homing Post AMI 
 Following acute myocardial injury, endogenous bone marrow stem 
cells mobilize and home into the infarct zone to attempt cardiac repair 
(Shintani et al., 2001). The stem cell homing to the myocardium is by 
signaling between stromal cell derived factor-1 (SDF-1) and its cognate 
receptor chemokine receptor type 4 (CXCR4). Endothelial and stromal 
cellular lining of the bone marrow stem cell niche constitutively expresses 
SDF-1, which interacts with its cognate receptor CXCR4 expressed on the 
stem cells (Dar et al., 2005; Imai et al., 1999; Ponomaryov et al., 2000). 
During homeostasis, endogenous bone marrow stem cells continually and 
variably egress into the blood stream in a circadian cyclical manner. These 
circadian changes in the levels of circulating bone marrow stem cells is 
under sympathetic control via noradrenaline binding to beta3-adrenoceptors 
on bone marrow stromal cells to decrease expression of SDF-1 and reduced 
CXCR4 signaling (Mendez-Ferrer et al., 2008). These daily changes in bone 
marrow stem cell mobilisation are, however, slow and peak 5 h following 
exposure to light (Mendez-Ferrer et al., 2008). In stress or pathological 
states, e.g. following AMI there is an elevation of SDF-1 in the heart, which 
intravasates to create a chemokine or SDF-1 gradient between the bone 
marrow stem cell niche and site of the myocardial infarction for trafficking 
of mobilised stem cells (Askari et al., 2003; Ceradini et al., 2004; Jiang et 
al., 2002; Wojakowski et al., 2004). Taking into account that SDF-1 is 
highly expressed by the bone marrow stem cell niche (Sugiyama et al., 
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2006), a rapid and massive intravasation of bone marrow stem cells would 
require a commensurate reduction in SDF-1 activity within the bone marrow 
niche.  That the endogenous bone marrow stem cell mobilisation is 
inadequate, exogenous cell delivery might be most beneficial if delivered 
before the onset of ischaemia or soon after the onset of reperfusion.  Thus 
far, clinical trials delivered bone marrow derived stem cells more than 4 
days following an AMI (Chen et al., 2004; Janssens et al., 2006; Lunde et 
al., 2006; Meyer et al., 2006; Schachinger et al., 2006). 
1.2.4 Regenerative and Non-regenerative Benefits of Adult 
Stem Cell Therapy 
The regenerative benefits of the injected stem cells are dependent 
upon the engraftment number, within an ischaemic or reperfusing 
myocardium. The engraftment number will in turn determine the number of 
cells that undergo differentiation and the lineage of differentiation will 
determine the functional benefit. Moreover, in the heart the appropriately 
differentiated cells must also achieve electromechanical connectivity with 
the remaining syncytium to improve cardiac function. Thus far, the 
engraftment number of donor cells is very low. Most cells are lost 
immediately after injection, regardless of donor cell type or the modality of 
cell injection (Hou et al., 2005).  Moreover, there is a high rate of loss of 
those cells that achieve initial engraftment (Muller-Ehmsen et al., 2006).  
This low rate of myocardial engraftment and subsequent retention is poorly 
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understood and if it remains so, the regenerative benefits of stem cell 
therapy may remain elusive.  
The differentiation of engrafted adult stem cells into the component cells 
necessary for myocardial regeneration remains controversial. The 
differentiation of MSCs into cardiomyocytes has been demonstrated in vitro 
by the application of 5-azacytidine (Makino et al., 1999). Further, co-
cultures of MSCs with cardiomyocytes have suggested differentiation is 
possible together with electromechanical integration (Fukuhara et al., 2003). 
Furthermore, in vivo differentiation of bone marrow haematopoietic stem 
cells into de novo myocardium has been the most powerful evidence 
suggesting regenerative benefit of adult stem cells in AMI (Orlic et al., 
2001). This evidence for regenerative benefit was, however, challenged by 
in vivo data that suggested that bone marrow derived haematopoietic stem 
cells could not transdifferentiate into the component cells necessary to 
regenerate myocardium (Balsam et al., 2004; Murry et al., 2004). 
Interestingly, other data suggest that engrafted bone marrow derived stem 
cells do not transdifferentiate but acquire a cardiomyocyte phenotype by 
fusing with the native cardiomyocytes both in vitro and in vivo (Garbade et 
al., 2005; Ishikawa et al., 2006; Nygren et al., 2004).     
Non-regenerative benefits following stem cell engraftment into the 
native myocardium are important for the functional improvement associated 
with adult stem cell therapy. It is not entirely clear whether these non-
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regenerative benefits exclude or enhance the regenerative benefits. Adult 
bone marrow derived stem cells  secrete a number of anti-apoptotic factors, 
angiogenic factors, growth factors, and cytokines that contribute to 
improvements in  cardiac function (Gnecchi et al., 2006; Kamihata et al., 
2001; Kinnaird et al., 2004; Uemura et al., 2006). Experimental studies 
have shown increased myocardial blood flow and capillary density, 
independent of newly formed vessels after injection of bone marrow derived 
stem cells following AMI (Iwasaki et al., 2006). These non-regenerative 
benefits of adult stem cell therapy might be due to up regulated angiogenic 
factors as secreted by the engrafted cells (Kamihata et al., 2001; Kobayashi 
et al., 2000). The secreted angiogenic factors from the engrafted bone 
marrow derived stem cells include vascular endothelial growth factor 
(VEGF), fibroblast growth factor (FGF), transforming growth factor-beta 
(TGF-β), platelet-derived growth factor (PDGF), hepatocyte growth factor 
(HGF), hypoxia inducible factor-alpha (HIF- α), and angiopoietins 
(Takahashi et al., 2006) and these could enhance neovascularization in the 
native myocardium (Matsunaga et al., 2000; Tomanek et al., 2004). Bonaros 
et al., also report that cell therapy attenuates apoptosis of the native 
cardiomyocytes by enhancing neoangiogenesis and increasing blood supply 
to the native myocardium in a rat experimental model (Bonaros et al., 
2006). In addition, Gnecchi et al., and Uemura et al., suggested that growth 
factors released from the donor cells, such as VEFG, FGF, HGF or insulin-
 
 
47 
 
like growth factor (IGF)-1, have an anti-apoptotic effect on the native 
cardiomyocyte following AMI (Gnecchi et al., 2006; Uemura et al., 2006). 
Although it used to be considered that adult cardiomyocytes are 
terminally differentiated cells and have no resource for regeneration, Quaini 
et al., identified new mature cardiomyocytes of recipient origin in the 
gender-mismatched transplanted human myocardium (Quaini et al., 2002) 
suggesting that endogenous stem cells might be able to be recruited to the 
donor heart and differentiate into mature cardiomyocytes. This evidence 
encouraged experimental and clinical studies for cytokine administration, 
such as granulocyte-colony stimulating factor (G-CSF) or stem cell factor 
(SCF), to increase BM-derived circulating stem cells and consequently 
enhance recruitment of the stem cells into the heart to regenerate the 
damaged myocardium. However, data from the experimental studies are 
inconsistent (Dawn et al., 2006; Fukuhara et al., 2004) and clinical studies 
showed no effects of G-CSF/SCF therapy on global cardiac function 
following acute MI (Engelmann et al., 2006; Zohlnhofer et al., 2006). 
Hou et al., suggested that cell injection into the rat heart up regulated 
stromal cell derived-1 factor (SDF-1) in the myocardium (Hou et al., 2005), 
which was reported to enhance homing of circulating stem cells into the 
tissue (Abbott et al., 2004; Askari et al., 2003) and, consequently, 
regenerate the damaged myocardium. Moreover, Beltrami et al., and Oh et 
al., reported the presence of residential stem cells in the adult myocardium, 
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which are capable of differentiating into mature cardiomyocytes both in 
vitro and in vivo (Beltrami et al., 2003; Oh et al., 2003) However, little is 
known about effects of cell therapy on recruitment of these endogenous 
stem cells into the heart. 
Impairment of diastolic function is the earliest consequence of AMI, 
and the reduction in LV diastolic compliance is due to extracellular oedema, 
cellular infiltration and finally fibrosis. Fibrosis or collagen deposition 
within the extracellular space and hypertrophy of the non-infarcted 
myocardium is necessary for post AMI ventricular remodeling (Pfeffer and 
Braunwald, 1990). Post AMI  collagen accumulation in the heart is known 
to be induced by an imbalance between synthesis and degradation of ECM, 
which is regulated by several pro-inflammatory cytokines, 
metalloproteinases (MMP), tissue inhibitor of metalloproteinase (TIMP) and 
growth factors (Spinale 2002). Ventricular remodeling improves LV 
function and prevents paradoxical systolic wall motion of the infarct zone. 
However, adverse ventricular remodeling leads to ventricular dilatation and 
heart failure. Experimental studies have shown that cell therapy decrease 
ECM collagen deposition and improve diastolic LV function of the heart 
post AMI (Jain et al., 2001). 
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1.3 Aims of Thesis 
The debate as to whether adult bone marrow stem cells can 
regenerate the heart following AMI continues. The low engraftment 
numbers of the exogenous adult stem cells, irrespective of the stem cell type 
or the modality of administration, does not favour regeneration of the 
ischaemia-injured myocardium. The homing mechanism of either 
exogenous or endogenous stem cells to the ischaemic myocardium relies 
upon the expression of SDF-1, which is the most powerful stem cell 
chemokine known to date. It therefore follows that the stem cell myocardial 
homing might be optimal when injecting exogenous stem cells at the peak 
of SDF-1 expression, i.e. at the end of ischaemia or at the beginning of 
reperfusion. Although this timing strategy may be optimal for stem cell 
homing to the myocardium, their subsequent survival may be suboptimal by 
exposure to the high levels of inflammatory mediators and oxidative stress 
typically associated with the I/R injury. The survival of the adult stem cell 
post myocardial homing might be relevant to their subsequent 
differentiation for regenerative benefits, but it is not imperative for non-
generative benefits. In other words, exogenous stem cell therapy might be 
primarily for delivering pro-survival factors and if this significantly reduced 
I/R injury, then the regenerative benefit may not be necessary. The role of 
the vast endogenous bone marrow stem cell reservoir during AMI is yet to 
be been fully elucidated. There is increased mobilization of endogenous 
bone marrow stem cells in response to increased myocardial SDF-1 
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expression during myocardial ischaemia. In the absence of ischaemia, this 
SDF-1 cross talk with the bone marrow may not take place. Upon 
reperfusion, SDF-1 signaling appears to be inadequate. Nevertheless, 
enhanced endogenous bone marrow stem cell release co-incidental with 
exogenous stem cell therapy might provide additional stem cell derived 
benefit. The aim of this thesis is to investigate the non-regenerative benefits 
of adult bone marrow derived stem cells. I hypothesised that systemic IV 
delivery of adult bone marrow derived stem cells is cardioprotective when 
delivered at the onset of reperfusion. I tested this hypothesis in a Wistar 
male rat model of regional myocardial ischaemia and reperfusion and I 
investigated the following: 
1. Whether IV BMMNC therapy upon reperfusion attenuates the 
injury caused by regional myocardial I/R (chapter 3). 
2. Whether IV BMMNC therapy upon reperfusion is associated 
with known cardioprotective molecular mechanisms (chapter 4).  
3. Whether adult bone marrow derived MSC by cell culture is  
cardioprotective in regional myocardial I/R (chapter 5) 
4. Whether regional myocardial I/R and IPC modulate mobilisation 
of endogenous bone marrow mononuclear cell by SDF-
1/CXCR4 signaling (chapter 6).  
5. Whether combining IPC with adult bone marrow MSC therapy at 
the onset of reperfusion might afford better cardioprotection 
(chapter 7). 
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Chapter 2 
Materials and Methods 
The animal experiments described in this thesis are in adherence to 
(i) National Institute of Health guidelines on the use of experimental 
animals (ii) Home Office Guidance on the Operation of the Animals 
(Scientific Procedures) Act 1986, published by HMSO, London. Male 
Wistar rats weighing 250-350g were maintained in a Home Office approved 
facility, receiving standard chow and water ad libitum. Test compounds are 
from Sigma-Aldrich (UK), unless otherwise stated. 
2.1 Isolation of Bone Marrow Mononuclear Cells 
Adult donor bone marrow mononuclear cells (BMMNC) were isolated 
from whole bone marrow (BM) removed from the long bones of male 
Wistar rats. General anaesthesia (5% isoflurane) was prior to cervical 
dislocation and BM was collected from both the femurs and tibiae.  The BM 
was collected in ice cold Hank’s balanced salt solution (HBSS). Whole 
marrow suspension was centrifuged at 1,600 g for 5 min. The resulting 
pellet was resuspended in 1ml HBSS containing 10% v/v foetal bovine 
serum (FBS), penicillin 100 IU/ml, and streptomycin 100 mg/ml.  This BM 
cell suspension were loaded on discontinuous PercollTM gradient (55% and 
70%, GE Healthcare) and centrifuged at 1,600 x g for 30 min (Kamihata et 
al., 2001). The interlayer containing BMMNC was collected (Figure 
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2.1.1A). BMMNC were washed twice with diluted 10 × volume of HBSS 
with 10% FBS and centrifuged at 300 x g for 5 min. BMMNC were then 
resuspended in HBSS containing 10% v/v FBS, penicillin 100 IU/ml, and 
streptomycin 100 mg/ml on ice until required. BMMNC viability by trypan 
blue exclusion test, using an equal volume of trypan blue and cell 
suspension incubated for 5 min at 37˚C. Then 10 μl of this mixture placed in 
a haemocytometer (Neubauer, VWR) to count the number of unstained 
(viable) and stained (non-viable) BMMNC. BMMNC viability by trypan 
blue exclusion was 97.05 ± 0.3%. Phenotyping of isolated BMMNC was by 
fluorescence activated flow cytometry (FACS) using a CyAnTM ADP High-
Performance Flowcytometer (DakoCytomation) equipped with SummitTM 
software (DakoCytomation). Appropriately, 10,000-gated events were 
collected for univariate (log scale) histogram plots. Phenotype 
characterisation of BMMNC by FACS flow cytometry for the 
haematopoietic stem cell markers c-Kit+, CD 34, CD 45, and CD 133 is 
shown in Figure 2.1.2. 
  BMMNC were washed twice with PBS to remove residual Percoll 
prior to re-suspension of 10 million cells in 0.5ml PBS. BMMNC 
administration was by a single IV bolus via a polypropylene catheter sited in 
the jugular vein of the animal. 
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1  
Figure 2.1.1 Isolation of adult bone marrow mononuclear cells (BMMNC) by Percoll 
density gradient centrifugation of ex vivo Wistar male rat whole bone marrow.  
(A) BMMNC separated from other cells into the cell layer indicated by the white arrow.  (B) 
BMMNC imaged by light microscopy in a haemocytometer for cell counting (mag. x 200). 
 
 
 
A
B
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Figure 2.1.2 Bone marrow mononuclear cell (BMMNC) phenotyping by FACS flow 
cytometry.   When compared to the isotype control antibody, BMMNC were positive for 
the haematopoietic stem cell markers c-Kit (7 ± 1%, n = 10), CD 34 (7 ± 1%, n = 10), CD 
45 (54 ± 6 %, n =10), CD 133 (15 ± 1%, n = 10), and CD 11b (12 ± 1%, n = 3). BMMNC 
viability by exclusion of propidium iodide was high at 98 ± 0.6 %. 
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2.2 Generation of Bone Marrow Mononuclear Cell 
Supernatant  
BMMNC supernatant (BMS) containing potential paracrine 
cytoprotective factors was generated by incubating a defined number of 
freshly isolated unfractionated BMMNC in 0.5 ml PBS. The concentrations 
of the BMMNC used to generate the BMS were 10 million, 20 million, 50 
million, and 100 million BMMNC. The period of BMMNC incubation in 
PBS was for a period of either 2 h or 24 h, at 37°C in a cell culture incubator 
with humidified air containing 5% CO2. Following this period of incubation, 
BMMNC removal was by centrifugation at 1600 x g and filtration through a 
20 μm filter. The cell free donor BMS injection was into an IV catheter sited 
in the jugular vein of the experimental animal.  
2.3 Isolation of Bone Marrow Mesenchymal Stem 
Cells  
Wistar male rats euthanized by inhalation of 5% isoflurane and cervical 
dislocation were used to remove BM from femurs and tibiae. Following 
animal sacrifice, BM was collected in complete culture media: 10ml alpha-
Modified Eagles Medium (α-MEM) + 1% glutamine + penicillin 100U/ml + 
streptomycin 100mg/ml, and 5% foetal bovine serum.  The mesenchymal 
stem cell (MSC) isolation from the other bone marrow cells was by virtue of 
their adherence to a plastic surface. The BM obtained from femurs and tibae 
was centrifuged (1500 rpm for 5 min) and resuspended in complete culture 
medium for subsequent culture in T75 cell culture flasks. Non-adherent cell 
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removal was by repeat washes with complete culture media at the following 
times: 1, 2, 6, 12, 24, 48 and 72 h. The plastic adherent cell had media 
changes every 48 h and passage at 70% confluence by 0.25% trypsin-EDTA 
for 5 min in a 37oC incubator with 5% CO2. At each passage, cells’ 
reseeding density was 1.5 x 105/cm2. Culture expansion of plastic adherent 
cells was demonstrable beyond passage number 25, however; only cells 
obtained from cultures less than passage number 13 were used in vivo 
experimentation.  
The mobilisation of MSC was by removal of the culture medium and 
incubation with 5ml 0.25% trypsin-EDTA for 5 min in a 37oC incubator 
with 5% CO2. The disassociated cells were collected in 1ml Hank's Buffered 
Salt Solution (HBSS), centrifuged 1500 rpm for 5 min, and resuspended in 
100 µl HBSS.  
Culture expanded plastic adherent cells were phenotyped for expression 
of haematopoietic lineage markers (CD 34, c-Kit, CD 45, CD 133); matrix 
receptors (CD 44); integrins (CD 29, CD 90). Cell viability was by 
exclusion of propidium iodide. Primary antibody for each cell surface 
marker was by incubation of one million cells with monoclonal antibody for 
30 min on ice. Washing the cells with 1 ml HBSS, centrifugation (1500 rpm 
for 5 min), resuspension in 100 µl HBSS, and repeat removed unbound 
antibody. Secondary antibody binding to primary antibody was by 
incubation for 30 min on ice and washing twice with HBSS (1ml). Cells are 
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resuspended in 500µl 2% paraformaldehyde (PFA) in PBS and analyzed by 
Fluorescence activated cell sorting (FACS) flow cytometry using a 
DakoCyan flowcytometer equipped with Summit v4.3 software (Dako, 
UK).FACS data collected 10,000 cellular events using 3-decade logarithmic 
amplification. FACS phenotyping of MSC is presented in Figures 2.3.2 & 
2.3.3. 
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Figure 2.3.1. Adult mesenchymal stem cells (MSC) isolated from ex vivo Wistar male 
rat whole bone marrow and expanded in culture. This light microscope image 
demonstrates plastic adherent MSC with a typical fibroblast appearance and confluent 
growth in a T75 cell culture flask (mag x100). 
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Figure 2.3.2 Culture expanded adult bone marrow derived mesenchymal stem cell 
(MSC) phenotyping by FACS flow cytometry for the R1 gated cell population as 
shown in the scatter plot. MSC isolated from BM and following culture expansion were 
phenotyped at passage 3. When compared with the isotype control antibody, MSC were 
positive for CD 90 and CD 29.  
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Figure 2.3.3 Culture expanded adult bone marrow derived mesenchymal stem cell 
(MSC) phenotyping by FACS flow cytometry following expansion to passage 3. When 
compared with the isotype control antibody, MSC were negative for the haematopoietic 
stem cell markers CD34, c-Kit, CD133, CD45, CD44, and CD11b. MSC viability by 
exclusion of propidium iodide was high at 98.8%. 
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2.4 Regional Myocardial I/R  
Anaesthetised male Wistar rats were subjected to LAD ischaemia and 
reperfusion (I/R). General anaesthetic was with thiopentone (Intraval 120 
mg/kg i.p.).  Tracheal intubation was necessary for ventilation of the animals 
with a small animal ventilator (Harvard Apparatus Ltd., Edenbridge, Kent. 
U.K.), so that thoracic entry for access to the heart was possible without loss 
in effective ventilation. The ventilator settings: 30% inspired oxygen, at a 
rate of 70 mandatory ventilations per min, and a tidal volume of 8-10 ml/kg.  
The body temperature monitoring was with a rectal probe thermometer and 
maintenance at 37±1oC was with a homoeothermic blanket unit (Harvard 
Apparatus Ltd., Edenbridge, Kent. U.K.).  A right carotid artery cannulation 
was necessary for mean arterial pressure (MAP) and heart rate (HR) 
transducer monitoring (Senso-Nor 840, Senso-Nor, Horten, Norway) with a 
data acquisition system (Mac Lab 8e, ADI Instruments, Hastings, UK) in 
line with a Dell Dimension 4100 desktop computer. Right jugular vein 
cannulation was necessary for IV administration of fluids.  The heart 
exposure was via a left thoracotomy incision. The pericardium dissected 
from the heart to expose the left anterior descending (LAD) coronary artery 
and snared proximally with a 7-0 mersilk suture (Ethicon, UK). The LAD 
occlusion begins, after having achieved haemodynamic stabilization and 
acclimatization over a 30 min period, at time 0 with a snare occlusion 
device (Figure 2.4.1). The LAD territory ischaemia confirmation was by 
anterior LV visual colour changes and ST segment elevation of the 
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electrocardiogram (Figure 2.4.1B). Following the 25 min period of LAD 
occlusion, LAD ligature release allows reperfusion to commence and 
continue for a defined period. The MAP and HR was noted from baseline 
(prior to onset of myocardial ischaemia) and throughout regional myocardial 
I/R.  The pressure rate index (PRI), a relative indicator of myocardial 
oxygen consumption (Baller et al., 1980), is a product of MAP and HR and 
expressed in mmHg min-110-5.  Boluses of IV saline (1 ml/kg/h) via the 
central venous cannulation were at every 30 min intervals throughout 
reperfusion. 
The generic regional I/R protocol and BM derived stem cell therapy by IV 
injection upon reperfusion is shown in Figure 2.4.2.  
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Figure 2.4.1 An anaesthetized male Wistar male rat with the heart exposed and 
subjected to LAD occlusion. The LAD territory myocardial ischaemia confirmation 
was by anterior LV immediate cyanotic colour change and the ST segment elevation, 
which is notable in the representative electrocardiograms from A to B. At end of 2 h 
reperfusion, transmural infarction was notable by Q-wave development in the 
electrocardiogram shown in C. 
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Figure 2.4.2 Generic regional I/R protocol and BM derived stem cell therapy by IV 
injection upon reperfusion. The generic Wistar male rats myocardial regional I/R 
protocol. Following general anaesthesia and surgical manipulation a 30 min of pre-
ischaemia stabilisation was allowed, which was proceeded  by 25min LAD occlusion and a 
defined period LAD reperfusion. For the specific period period of reperfusion see methods 
section the relevant chapter. Sham animals underwent the same anaesthesia and surgery but 
no LAD occlusion (I/R). 
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2.5 Myocardial Infarct Size post Regional I/R 
Following regional I/R, the identification of the LAD territory subjected 
to I/R was by LAD re-occlusion and injection of Evans Blue dye (1 ml of 
2% w/v) via the right internal jugular vein cannulation.  The Evans Blue 
solution stains the perfused myocardium, while area of the LV subjected to 
I/R (area at risk) remains unstained. Immediately, after identification of the 
area at risk (AAR) the animal was euthanized with an overdose of 
anaesthetic to excise the heart. The explanted heart was then immediately 
subjected to  transverse or short axis 3–4 mm slices, to excise the unstained 
AAR from the blue stained non-ischaemic myocardium, which included the 
right ventricle and part of the left ventricle. The AAR was further cut into 
small pieces for identification of viable from non-viable myocardium by 
incubation of the AAR with 0.5mg/ml p-nitro blue tetrazolium (NBT) for 20 
min at 37°C. Viable myocardium with intact dehydrogenase enzyme 
systems converts the NBT into a dark blue formazan, whilst the  infarcted 
AAR lack dehydrogenase activity and therefore fails to stain (Nachlas et al., 
1963). The weight of unstained AAR was expressed as a percentage of the 
total weight of the AAR, which is the myocardial infarct size or the primary 
end-point. 
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2.6 Isolation of Cardiomyocytes post Regional I/R 
Cardiomyocyte isolation from the LV region post I/R was as previously 
described (Mitra et al., 1985), with some modifications. Following 25 min 
LAD occlusion and 2 h reperfusion, the whole heart was explanted and 
perfused with 20 ml cold (0-4˚C)antegrade coronary cardioplegia solution at 
a rate of 2 ml/min via a cannula placed in the ascending aorta. Immediate 
cardiac arrest was achieved using ice-cold cardioplegia bicarbonate buffer 
(CBB) solution (AQIX® RS-I). Next perfusate was warm 20 ml (37˚C) CBB 
containing collagenase (Gibco) and protease, via the aortic cannula. Final 
perfusate was 20 ml warm (37˚C) CBB containing protease inhibitor was 
via the aortic cannula. The area of the left ventricle at risk from I/R injury 
(AAR) was demarcated by re-occluding the LAD and injecting Evans 
blue antegrade via the aortic cannula. The unstained AAR was excised, 
finely diced and gently pressed through a 300 µm steel sieve to release the 
cells. The AAR cell suspension was centrifuged and washed twice with cold 
CBB solution (AQIX® RS-I). The isolated AAR cells were suspended in 
cold buffer solution (AQIX® RS-I) and stored on ice, prior to staining for 
subsequent fluorescent-activated cell sorting (FACS) flow cytometric 
analysis. Figure 2.6.1 shows isolated cardiomyocytes from the AAR as seen 
under light microscopy.  
Isolated AAR cell binding to a Troponin-T monoclonal antibody was also 
checked to ensure that the isolated cells were indeed cardiomyocytes. 
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Incubation of the putative cardiomyocytes with a primary mouse 
monoclonal antibody for cardiac Troponin-T (Santa Cruz, USA), was for 30 
min on ice. Unbound antibody removal was by washing the cells twice and 
then incubation with a goat anti-mouse antibody conjugated with fluorescein 
isothiocyanate (Santa Cruz, USA). Figure 2.6.2 shows the FACS flow 
cytometry analysis of isolated cardiomyocytes for the Troponin T binding.   
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Figure 2.6.1 Isolated cardiomyocytes (A) lower power (mag x 200) and (B) high power 
microscopy (mag x400) 
A 
B 
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Figure 2.6.2 FACS flowcytometry of isolated cardiomyocytes. (A&B) Respective FACS 
flow cytometry scatter plots of side scatter versus FL1 for cardiomyocytes stained with the 
isotype control and Troponin T antibodies both conjugated with FITC. (C) Overlay 
histogram plot for cardiomyocytes stained with isotype control and Troponin T antibodies 
conjugated with FITC. 
 
Isotype Control 
Troponin T: 83 ± 5% 
Isotype control Troponin T 
C 
A B 
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2.7 Cardiomyocyte Apoptosis and Necrosis post 
Regional I/R 
An apoptosis detection kit was used to dual stain cardiomyocytes 
isolated from the AAR with Annexin-5-FITC and propidium iodide, as per 
kit instructions (BD Biosciences Pharmingen). Unstained cells were 
negative controls. The AAR cardiomyocyte staining and analysis was within 
1 h of cell isolation. Dual stained cell analysis was by a Becton Dickinson 
FACScan flow cytometer (BD FACScan, UK) and equipped with Cell-
Quest software (BD). The flowcytometer gating was set to collect 10,000 
cells from each sample with logarithmic gain settings. Annexin-5 and 
propidium iodide cannot permeate an intact plasma membrane and so will 
not stain viable cells. Annexin-5 will avidly bind to the inner membrane 
phospholipid phosphatidylserine, which becomes externalised by cells 
undergoing apoptosis. Cells that have lost membrane integrity will not only 
stain positive for Annexin-5 but they will concomitantly stain with 
propidium iodide, which binds to nuclear deoxyribonucleic acid (DNA).  
Dual staining of AAR cardiomyocytes with annexin-5-FITC and propidium 
iodide was analyzed by FACS flow cytometry to identify cells that were 
either apoptotic (annexin-5+/PI−) or necrotic (annexin-V+/PI+). Quadrant 
percentiles for apoptosis and necrosis.  
Detection of activated caspase 9 activation in AAR cardiomyocytes 
was to distinguish between apoptosis by intrinsic or extrinsic mechanisms. 
AAR cardiomyocytes stained with caspase 9 assay kit based upon 
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Fluorescent Labeled Inhibitor of Caspases (FLICA) reagent FAM-LEHD-
FMK, which is a non-toxic membrane permeable fluorescent probe. The 
LEHD peptide sequence within the FLICA binds avidly to and inhibits 
activated caspase 9. Bound FLICA will remain inside the cell to give a 
direct measurement of the number of active Caspase 9 molecules that were 
present at the time of addition of  FLICA reagent. Unbound FLICA is easily 
washed from either necrotic or viable cells. FACS flow cytometry detects 
the fluorescent FAM moiety bound to FLICA and so quantifies activated 
Caspase 9.  
2.8 Cardiac Function post Regional I/R 
  The cardiac function post regional I/R was assessed at the end of 7 
days of reperfusion (I/R-7D). The protocol for regional I/R was altered to 
enable recovery of the animals and this is briefly described. Animals were 
anaesthetised by inhalation of 1.5% isoflurane and mechanical ventilation 
was commenced following endotracheal intubation at a tidal volume of 200 
ml/min using a Harvard small animal ventilator. The heart exposure was via 
a left thoracotomy and the LAD was isolated with a 6-0 polypropylene 
suture (Bear Medic). The LAD occlusion was with a reversible occluder for 
25 min, and anterior regional ischemia confirmed by an ischaemic colour 
change and S-T segment elevation on the electrocardiograph. Following 25 
min LAD occlusion, the occluder release allows reperfusion, which 
continues for 7 days. The thoracotomy closure was with a 4-0 
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polypropylene suture (Bear Medic), and then the termination of the 
anaesthetic allowed spontaneous post procedural recovery.  Post recovery 
animals received prophylactic antibiotics and buprenorphine analgesia in 
their water. A standard diet was resumed upon return to the animal facility.  
Transthoracic 2-dimensional (2-D) echocardiography was used during 
general anesthesia using a Vevo-770 imaging system with a 17.5MHz small 
animal transducer probe (Vevo, Visual Sonics, USA). The anaesthetic (1.5% 
isoflurane) delivery was via a nose cone. Echo images acquisition was on 
the day before I/R and 7 days post I/R. Short axis views at the mid-papillary 
muscle level were used for assessment of the fractional area of LV 
contraction (% FAC). The LV ejection fraction (LVEF) assessment was by 
motion mode (M-mode).  
Haemodynamic LV catheter analysis was performed under anesthetic 
(1.5% isoflurane) delivered via a nose cone, on the day before and 7 days 
post I/R. A 2-Fr micro tipped pressure transducer (Millar Instruments; SPR-
320) was inserted into the LV cavity, via the right carotid artery, for 
measurement of LV pressures during the cardiac cycle. The following LV 
pressure were noted: peak systolic pressure (LVPSP), end diastolic pressure 
(LVEDP), maximal slope of systolic pressure increment (+dP/dt), diastolic 
pressure decrement (−dP/dt),  and the relaxation time constant (tau). The LV 
pressures and the heart rate were analyzed using LabChart Pro software (AD 
Instruments, UK). 
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2.9 Myocardial Fibrosis post Regional I/R 
Explanted hearts subjected to regional ischaemia and 21 days 
reperfusion were perfusion fixed with 1 ml ice-cold 4% paraformaldehyde 
via the aorta and then immersed in ice-cold 4 % paraformaldehyde for 30 
min. Hearts were then washed with PBS and incubated in PBS containing 
30% sucrose (w/v) at 4°C overnight. Fixed hearts were then sliced 
transversely into three pieces, embedded in OCT compound (BDH), and 
then frozen in liquid nitrogen-cooled isopentane for storage at -80°C. 
Subsequently cryosections (15-25 µm) from each segment were made using 
a rotary cryotome (Leica). Cryosections were placed on polysine-coated 
glass slides (VWR) and stained with 0.1% picrosirius red F3B (0.1 g Sirus 
red in 100 ml saturated aqueous picric acid, BDH) for 10 min at room 
temperature. The cryosections were rinsed 5 times in deionised water  and 
then rinsed for 1 min in picric alcohol (20 ml absolute alcohol; 70 ml 
deionised water; 10 ml saturated aqueous picric acid). The sections were 
then dehydrated through a methanol series and mounted in DPX (VWR). 
The degree of picrosirius red staining was visualised by a light microscope 
(Keyence, BZ8000). 
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2.10 Cell Signaling 
The AAR from 25 min LAD ischaemia followed by only 30 min 
reperfusion underwent analysis for cell signaling. AAR from the following 
animal groups were analysed by western blotting: (1) pre-treatment with 
LY294002 (0.3 mg/kg IV) followed by sham surgery. (2) Pre-treatment with 
PBS followed by 25 min LAD ischaemia and 30 min reperfusion with 
treatment upon reperfusion with either PBS or BMMNC. (3) Pre-treatment 
with the PI3K inhibitor LY294002 (0.3 mg/kg IV) followed by 25 min LAD 
ischaemia and 30 min reperfusion with treatment upon reperfusion with 
either PBS or BMMNC. The ex vivo AAR samples are snap frozen in liquid 
nitrogen and stored at -80 °C, for subsequent protein analysis by western 
blots.   
The protein extracts from AAR investigated for cell signaling  
extracted were from  cytosolic and nuclear fractions, as described (Meldrum 
et al., 1997). Briefly, AAR was homogenized (Wheaton, Millville, NJ, 
USA) 10% w/v in homogenization buffer containing 20 mM HEPES, pH 
7.9, 1 mM MgCl2, 0.5 mM EDTA, 1% NP–40, 1 mM EGTA, 1 mM 
dithiothreitol (DTT), 0.5 mM phenylmethyl sulphonyl fluoride (PMSF), 5 
μg/ml aprotinin, 2.5 μg/ml leupeptin. Homogenates centrifuged at 1000 × 
g for 5 min at 4 °C. Supernatants were removed and centrifuged at 105,000 
× g at 4°C for 40 min to obtain cytosolic protein fractions. Pelleted nuclei 
were resuspended in extraction buffer containing 20 mM HEPES, pH 7.9, 
1.5 mM MgCl2, 300 mM NaCl, 0.2 mM EDTA, 20% glycerol, 1 mM 
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EGTA, 1 mM DTT, 0.5 mM PMSF, 5 μg/ml aprotinin, 2.5 μg/ml leupeptin. 
The suspensions were incubated on ice for 30 min for high-salt extraction 
followed by centrifugation at 15,000 × g for 20 min at 4°C. The resulting 
supernatants containing DNA-binding proteins were carefully removed, 
protein content was determined using the Bradford assay (Bradford 1976) 
and samples were stored at − 80 °C. Western blots of the cytosolic protein 
extracts for phosphorylation of Akt, GSK-3, and p38 MAPK were as 
previously described (Collino et al., 2006). Western blots for the nuclear 
translocation of p65 NF-B was for protein extracts from both the cytosolic 
and nucleus fractions. Briefly, electrophoresis of 15µg of total protein 
extract was on 8% sodium dodecyl sulphate-polyacrylamide gel 
(SDSPAGE) followed by  transfer to a polyvinyldenediflouride (PVDF) 
membrane (Millipore, USA) for subsequent immersion in blocking buffer 
(Super Block, Pierce Biotechnology, USA). PVDF membrane incubation 
are then with the following a primary antibody. The primary antibodies 
were: mouse anti-rat phosphorylated Aktserine-473 (Cell Signaling 
Biotechnology, USA); rabbit anti-rat total Akt; rabbit anti-rat total GSK-3 
(Santa Cruz, California, USA); goat anti-rat phosphorylated GSK-3Serine-9 
(Santa Cruz,USA); goat anti-rat phosphorylated GSK-3Tyrosine-216 (Santa 
Cruz); mouse anti-rat phosphorylated p38 MAPK (Cell Signaling 
Biotechnology, USA); and mouse anti-rat NF-κB p65 (Santa Cruz). Primary 
antibody binding detection was by incubation with appropriate secondary 
antibodies conjugated with horseradish peroxidase and development with an 
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enhanced chemiluminescence detection system (Amersham, UK). 
Assessment for loading homogeneity was by incubation of the stripped 
membrane in -actin monoclonal antibody and subsequently with anti-
mouse antibody. Membranes we evaluated for reactive immune bands by 
and quantification of band optical density was by Gel ProAnalyzer 4.5, 
2000 software (Media Cybernetics, USA). 
2.11 Proteomics post Regional Myocardial I/R 
Proteomics gives a quantitative analysis of all the proteins, including 
their post-translational modifications, expressed by the genome at any given 
point in time (Wilkins et al., 1996). Proteomic data could therefore provide 
valuable insight into altered protein expression and associated pathology 
(Huber et al., 2003; Lopez et al., 2002; Loscalzo 2003; Mcgregor et al., 
2003).Thus the differential expression of proteins extracted from the 
ischaemic and reperfusing myocardium can give insight into underlying 
mechanisms of injury and protection. The resolution of proteins by 2-
dimensional gel electrophoresis (2-DE) remains the preferred method to 
date (Gorg et al., 2004). 2-DE can resolve up to 5000 proteins 
simultaneously with detection and quantification of <1ng of protein per 
spot. There is no current technological match for 2-DE, which permits 
routine parallel expression profiling of a large complex of proteins. It 
delivers a map of intact proteins that reflect changes in protein expression 
level, isoforms, and post-translational modifications. I investigated the 
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effect of BMMNC and BMS on the differential expression of proteins 
within the area at risk (AAR) of the LV subjected to 25 min ischemia and 2 
h reperfusion (I/R-2h).The AAR analyzed was from hearts treated upon 
reperfusion by, PBS, BMMNC, BMS or sham (no I/R-2h). At the end of 
I/R-2h, the excised AAR was snap frozen in liquid nitrogen and stored at -
80°C, for later proteomic analysis.  
Protein extraction from thawed AAR tissue was previously described 
(De Roos et al., 2005). Briefly,  proteins were extracted from 300mg of 
tissue and 1.2ml of extraction buffer (Ultrapure Urea 40% w/v, Thiourea 
15.2% w/v, CHAPS 4% w/v, Ampholyte 5% v/v; Bio-Rad, USA). Tissue 
from AAR was homogenised and then sonicated for 3 x 10 seconds periods 
with 3 min intervals between each sonication to allow cooling. Then 
samples were centrifuged at 14000 rpm in Eppendorf tubes and proteins in 
the supernatant were then separated according to size and charge by 2-DE in 
SDSPAGE gels, as previously described (De Roos et al., 2005).  Separated 
proteins spots, after staining with Coomassie Brilliant Blue, were scanned 
(GS-800 calibrated densitometer, BioRad, USA) and analyzed for 
differential protein spot expression (PDQuest Advanced 8.02, Bio-Rad, 
USA). Then an automated robotic protein handling system, which excised 
selected gel spots, with optical densities that were significantly different, for 
trypsinisation (EXQuest Spot Cutter and MassPREPTM, Bio-Rad USA). 
Trypsinised protein spot analysis was by liquid chromatography, 
electrospray ionisation, and tandem ion-trap mass spectrometry/mass 
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spectrometry (LC/ESI/MS/MS, Q-Trap 4000, Applied Biosystems, UK). 
The high performance liquid chromatography (HPLC) system was equipped 
with a 100-angstrom nanocolumn measuring 15 cm x 75 µm x 3 µm, (C18 
Pep Map 100, LC Packings, Camberly, Surrey, UK). Sample injection into 
the column by a Famos auto sampler was set to an injection volume of 5 µl 
and the column flow rate was 0.3 µl/min. The samples were eluted with 
HPLC grade solvents including 2% acetonitrile and 0.1% formic acid (A) 
and 80% acetonitrile and 0.08% formic acid (B). The column gradient 
started at 5% solvent B, increasing to 50% B over 30 min followed by a 
ramping up to 80% B over a further 2 min and held for a further 10 min. 
The system was equilibrated with 95% solvent A for 9 min prior to injection 
of peptides samples. HPLC column eluted peptides into the Q-Trap triple 
quadrupole mass spectrometer (MS). The MS was fitted with a nanospray 
ion source and the needle voltage was set at 2450 volts, with oxygen free 
nitrogen as the curtain gas and the collision gas. In the survey scan mode, 
the mass range was set to 400-1200 (mass/charge ratio) with a scan rate of 
4000 atomic mass units/second (amu/s). Criteria for selection of ions for 
fragmentation were set for ions of 105 counts per second or above. The 
collision energy was set to a maximum of 80 electron volts. The linear ion 
trap fill time was 250 milliseconds and the scan rate was 1000 amu/s. Total 
ion current data was submitted online to the MASCOT search engine 
(Matrix Science) using the MSDB database. The following search criteria 
were used : allowance of 0 or 1 missed cleavages; peptide mass tolerance of 
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± 1 Daltons (Da) ; fragment mass tolerance of ± 0.8 Da, trypsin as digestion 
enzyme; carabamidomethyl modification of cysteine; and methionine 
oxidation as partial modification.  
2.12 Statistical Analysis 
Prism 5 statistics package (Graphpad, USA) was used to analyse the 
results. All data presentation was means ± SEM, and analysed by one-way 
ANOVA followed by Dunnett’s post test for multiple comparisons. In the 
comparison of just two groups, Student’s unpaired t-test was used. 
Haemodynamic parameters analysis was by two-way ANOVA followed by 
Bonferroni’s post hoc test for multiple comparisons. A two-tailed P value < 
0.05 was considered to be statistically significant. For proteomic data, the 
pooled variance of the protein spots were compared by ANOVA and post-
hoc unpaired t-tests.  
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Chapter 3 
Bone Marrow Mononuclear Cell Therapy upon 
Reperfusion Attenuated Regional Myocardial 
I/R Injury 
3.1 Introduction 
The most effective route and optimal time point for the delivery of 
stem cells to an acutely ischaemic heart is still debatable. Stem cell injection 
to target the heart can be by (1) systemic intravenous (IV) i.e. systemic or 
retrograde coronary (2) intra-coronary (IC) (3) intra-myocardial (IM). 
Injection of cells by IM or IC routes suggests that high numbers of stem  
cells might directly target areas of the heart where stem cell therapy may be 
beneficial, however, significant risks may outweigh potential benefits. 
These risks include clustering or islands of stem cells within the 
myocardium following IM injection, which may interfere with 
electromechanical synchrony and  trigger dangerous cardiac arrhythmias 
(Leobon et al., 2003; Reinecke et al., 2002). Despite the advantage of a high 
initial deposition of stem cells following IM injection, these cells are rapidly 
lost from an ischaemic myocardium (Muller-Ehmsen et al., 2006). The 
antegrade IC injection also potentially delivers a high number of cells 
directly into the myocardial micro-circulation and relies on stem cell 
transmigration abilities to extravasate into the myocardium. Failure to 
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transmigrate, however, carries a high risk of intracoronary stem cell 
aggregation and distal embolization, which could compromise coronary 
perfusion and negate the potential benefits of cell therapy, particularly in the 
reperfusing heart (Suzuki et al., 2000; Vulliet et al., 2004). On the other 
hand, IV injection delivers a comparitively smaller number of donor cells 
directly to the heart due to the dilutional effects of the circulating volume 
and secondly due to extra-cardiac organ capture by the lungs, lymphatic 
tissue, and the bone marrow. There are, however, clinical advantages of IV 
delivery over that by IM and IC, which include a minimally invasive route 
of delivery, wide availability, comparatively low technical skill requirement 
for peripheral IV cannulations. Further, if the timing of stem cell delivery by 
IV coincides with the highest expression of SDF-1within the myocardium, 
i.e. at the end of ischaemia, exogenous stem cells could preferentially 
traffick down the SDF-1 gradient to the ischaemic myocardium. It is 
noteworthy, that this might not be the case if the cell delivery is pre-
ischaemia, in the absence of reperfusion, or if a long period of reperfusion 
has elapsed. This may explain, at least in part, why the clinical trials 
investigating autologous bone marrow mononuclear cell (BMMNC) therapy 
in AMI patients report very small improvements in cardiac function. 
Specifically, BMMNC delivery was typically 24 h after culprit coronary 
artery reperfusion (Chen et al., 2004; Janssens et al., 2006; Lunde et al., 
2006; Meyer et al., 2006; Schachinger et al., 2006).  
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BMMNC are easily harvestable and thus have been in investigated in 
clinical trials for treating AMI (Chen et al., 2004; Janssens et al., 2006; 
Lunde et al., 2006; Meyer et al., 2006; Schachinger et al., 2006). BMMNC 
contain primarily haematopoietic stem cells and their ability to regenerate 
regions of damaged myocardium, is controversial (Balsam et al., 2004; 
Jackson et al., 2001; Murry et al., 2004; Orlic et al., 2001). Further, 
BMMNC therapy in AMI might be improving cardiac function by secreting 
growth factors, angiogenic factors, and anti-apoptotic factors (Gnecchi et 
al., 2006; Kamihata et al., 2001; Uemura et al., 2006; Kinnaird et al., 2004). 
In this chapter, I investigated the effect of systemic IV syngeneic ex vivo 
BMMNC at the onset of reperfusion upon infarct size, cardiac function, and 
cardiac fibrosis in a rat model of regional myocardial I/R. 
3.2 Intravenous BMMNC Therapy upon Reperfusion 
and Myocardial Infarct Size 
3.2.1 Methods  
Donor BMMNC were freshly isolated from ex vivo BM expressed from 
the femurs and tibae of Wistar male rats, not subjected to regional 
myocardial I/Rinjury, as described in chapter 2. BMMNC were positive for 
c-Kit (7 ± 1%, n = 10), CD34 (7 ± 1%, n = 10), CD45 (54 ± 6 %, n =10), 
and CD133 (15 ± 1%, n = 10). BMMNC cell viability was 97.1 ± 0.3% (n = 
10). 
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Randomly selected Wistar male rats were subjected to regional 
myocardial ischaemia and reperfusion, by 25 min of LAD occlusion  
followed by 2 h of LAD reperfusion (I/R-2h), as described in chapter 2. 
Sham rats are subject to the same surgical procedure but not LAD occlusion 
and reperfusion. IPC was by two consecutive cycles of 5 min LAD 
ischaemia followed by 5 min LAD reperfusion, prior to the I/R-2h. Animals 
received either 0.5 ml PBS or 10 million BMMNC (in 0.5 ml PBS), via the 
internal jugular vein at the onset of reperfusion. At the end of reperfusion, 
infarct size measurement was by the method described in chapter 2 (Nachlas 
et al., 1963). The experimental groups are as indicated Table 3.2.1.1 
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Table 3.2.1.1 Experimental Design: BMMNC therapy and infarct size 
following 25min LAD ischaemia and 2 h reperfusion. Wistar male rats 
underwent either 25 min LAD occlusion and 2 h of LAD reperfusion (I/R-
2h) or no LAD occlusion i.e. sham procedure. IPC was by two consecutive 
cycles of 5 min LAD ischaemia followed by 5 min LAD reperfusion, prior 
to the I/R-2h. The n value is the number of animals per group. 
Group N Reperfusion Protocol  IV injection upon Reperfusion 
Sham 5 No I/R-2h 0.5 ml PBS 
PBS 5 I/R-2h 0.5 ml PBS 
IPC 9 IPC then I/R-2h 0.5 ml PBS 
BMMNC 10 I/R-2h 10 x106 BMMNC (0.5 ml PBS) 
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3.2.2 Results 
In Figure 3.2.2.1(A), left ventricular AAR from I/R-2h was similar 
between all the experimental groups. As shown in Figure 3.2.2.1(B), when 
compared with PBS (vehicle controls), IV bolus administration of 10 
million BMMNC upon reperfusion significantly attenuated myocardial 
infarct size due to I/R-2h (BMMNC 33 ± 3 %; PBS 57 ± 2 %, 1-way 
ANOVA and Dunnett’s post test, P < 0.001). Infarct size comparisons 
between BMMNC and IPC were, however, similar (P>0.05). The 
attenuation of infarct size by either BMMNC or IPC was independent of any 
effects due to variations in haemodynamic parameters between the groups 
as presented in Figure 3.2.2.2 (A-C): when compared with PBS, mean 
arterial pressure, heart rate, and pressure rate index, were similar between all 
experimental groups at all time points (2-way ANOVA, P>0.05). 
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Figure 3.2.2.1 BMMNC therapy and infarct size following 25min LAD ischaemia and    
2 h  reperfusion (I/R-2h) (A) Left ventricular area at risk (AAR) from I/R-2h was similar 
between all groups. (B) When compared to PBS (control), infarct size (% AAR) was 
significantly attenuated by a single IV bolus of 10 million BMMNC upon reperfusion (1-
way ANOVA and Dunnett’s post test, P<0.001, n=10). Infarct size comparison between 
BMMNC and IPC was similar. Sham group underwent the same surgical procedure but no 
I/R-2h. 
Sham PBS BMMNC IPC
0
10
20
30
40
50
60
70
A
A
A
R
 (%
 L
V
)
Sham PBS BMMNC IPC
0
10
20
30
40
50
60
70 P< 0.001
B
In
fa
rc
t S
iz
e 
(%
 A
A
R
)
 
 
87 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2.2.2 Haemodynamic variability during 25min LAD ischaemia and 2 h 
reperfusion. When compared with PBS (control) alterations in (A) mean arterial pressure 
(MAP), (B) heart rate (HR), and (C) pressure rate index (PRI) were similar between all 
experimental groups (2-way ANOVA, P > 0.05). 
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3.3 Intravenous BMMNC Therapy upon Reperfusion 
and Left Ventricular Function 
3.3.1 Methods 
 Assessment of LV function in Wistar male rats was by transthoracic 
2-D echocardiography and LV pressure transduction catheter as described in 
chapter 2. Assessment of LV function in animals was pre and post 25 min of 
left anterior descending coronary artery (LAD) occlusion and reperfusion 
for 7 days (I/R-7D). A delay of 7 days before assessment of LV function is 
to allow for the resolution of post-ischaemic ventricular stunning 
(Braunwald et al., 1982) and optimisation of the echocardiographical image 
quality following surgical thoracotomy. Following 25 min LAD occlusion, 
animals received either a single bolus IV of 10 million BMMNC or PBS 
(vehicle), at the onset of reperfusion. Approximately, 1 h following the 
onset of reperfusion, the thoracotomy wound was closed and the anaesthetic 
discontinued. I carried out all the surgical steps and following I/R-7D the 
LV functional data  acquisition and data analysis (2-D echocardiography 
plus LV pressure transduction catheter) was by blinded observers. The 
experimental groups were as shown in Table 3.3.1.1. 
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Table 3.3.1.1 Experimental Design: BMMNC therapy and LV function  
following 25min LAD ischaemia and 7 days reperfusion. Wistar male 
rats underwent either 25 min LAD occlusion and 7 days of LAD reperfusion 
(I/R-7D) or no LAD occlusion i.e. sham procedure. The n value is the 
number of animals in each group. 
Group N Reperfusion Protocol IV Injection upon Reperfusion 
Sham 10 No I/R-7D 0.5 ml PBS 
PBS 10 I/R-7D 0.5 ml PBS 
BMMNC 10 I/R-7D 10 x 106 BMMNC (0.5 ml PBS) 
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3.3.2 Results 
 In Figure 3.3.2.1, representative images of transthoracic 2-D echo 
used for the assessments of LV function show comparative M-mode images 
for sham, PBS and BMMNC animals. In Figure 3.3.2.2, when compared 
with BMMNC, both left ventricular ejection fraction (LVEF) and left 
ventricular area of contraction (FAC) were significantly attenuated for the 
PBS (vehicle control) group: LVEF (BMMNC 71 ± 3 % vs. PBS 48 ± 4 %, 
n = 10, P < 0.0001) and FAC (BMMNC 47 ± 2 % vs. PBS 36 ± 3 %, n = 10, 
P < 0.01). There were no significant differences in both the LVEF and FAC 
when comparing BMMNC with the sham group. 
In Figures 3.3.2.3 and 3.3.2.4, the LV pressure transduction catheter 
derived parameters used to assess LV systolic function and diastolic 
function. Owing to technical difficulties, it was not possible to catheterize 
the LV in three animals. The LV pressure transduction catheter derived 
parameters used to assess systolic function were peak rate of increase of LV 
pressure (dP/dtmax) and contractility index. Both dP/dtmax and the 
contractility index were significantly reduced in the PBS treated group, as 
compared with the BMMNC group: dP/dtmax (BMMNC 10 x 103 mmHgs-1  
± 0.4 % vs. PBS 8 x 103 mmHgs-1 ± 1 % n = 7, P < 0.05); Contractility 
Index (BMMNC 162 ± 10 vs. PBS 113 ± 3, n = 7, P < 0.001).  These results 
are concordant with the echocardiography derived LVEF and FAC. 
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Left ventricular diastolic dysfunction was demonstrated by an 
increase in left ventricular end-diastolic pressure (LVEDP), a decrease in 
the peak rate of decline in left ventricular pressure (-dP/dtmin), and an 
increase in the time constant of left ventricular pressure fall (tau ). When 
compared with PBS, LV compliance was significantly higher for BMMNC 
treated group; LVEDP (BMMNC 4 ± 1 mmHg vs. PBS 16 ± 3 mmHg, P < 
0.01); dP/dtmin (BMMNC -9 x 103  ± 0.5 mmHgs-1 vs. PBS  -7 x 103 ± 1 
mmHgs-1, P < 0.01); τ (BMMNC 10.2 x 10-3 ± 0.5 vs. PBS 12.3 x 10-3 ± 1, 
P< 0.05). These data suggest that the IV administration of BMMNC, upon 
reperfusion, preserved both systolic and diastolic function. 
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Figure 3.3.2.1   Representative transthoracic 2-D echo M-mode imaging. Assessment of 
LV function was following 25 min LAD ischaemia and reperfusion for 7 days (I/R-7D). 
When compared with PBS, LV function was significantly higher in animals treated with a 
single IV bolus of 10 million BMMNC upon reperfusion. The sham group underwent the 
same surgical procedure but no I/R-7D. 
 
 
 
 
 
Systole Diastole 
Diastole 
Diastole 
Systole
Systole 
PBS 
BMMNCC 
Sham 
 
 
93 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3.2.2 Transthoracic echocardiography following 25min LAD ischaemia and 
reperfusion for 7 days (I/R-7D). (A) When compared to PBS, the LV ejection fraction 
(LVEF) was significantly higher in animals treated by a single IV bolus of BMMNC (1-
way ANOVA and Dunnett’s post, P<0.0001, n=10). (B) When compared to PBS, LV 
fractional area of contraction (FAC) was also significantly higher for BMMNC (1-way 
ANOVA and Dunnett’s post test, P<0.01, n=10). 
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Figure 3.3.2.3 Left intraventricular pressure catheterisation following 25min LAD 
ischaemia and reperfusion for 7 days (I/R-7D). (A)When compared with PBS, rate of 
increase in systolic intraventricular pressure (dP/dtmax) was significantly higher in animals 
treated by a single IV bolus of 10 million BMMNC upon reperfusion (1-way ANOVA and 
Dunnett’s post test, P<0.05, n=7). (B) When compared with PBS, LV contractility index 
was also significantly higher for BMMNC animals (1-way ANOVA and Dunnett’s post 
test, P<0.01, n=7). 
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Figure 3.3.2.4 LV pressure catheterization following 25min LAD ischaemia and 
reperfusion for 7 days (I/R-7D). (A) When compared with PBS, LV end diastolic pressure 
(LVEDP) was significantly lower in animals treated by a single IV bolus of 10 million 
BMMNC, upon reperfusion (1-way ANOVA and Dunnett’s post hoc test, P<0.01). (B) 
When compared with PBS, decrease in diastolic left ventricular pressure (dP/dtmin) was also 
lower for BMMNC but not statistically significance (1-way ANOVA and Dunnett’s post 
hoc test, P=0.057). (C) When compared with PBS, LV diastolic time constant (Tau) was 
significantly lower for BMMNC (1-way ANOVA and Dunnett’s post hoc test, P<0.05). 
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3.4 Intravenous BMMNC Therapy upon Reperfusion 
and Cardiac Fibrosis 
3.4.1 Methods 
A qualitative assessment of the volume of extracellular collagen 
deposited following regional I/R was by picrosirius red staining of 
myocardial cryosections. Cryosections were made of hearts, acquired from 
Wistar male rats that had previously been subjected to 25min LAD 
occlusion and 7 days reperfusion for assessment cardiac function in the 
previous study. Thus, donor BMMNC from syngeneic Wistar male rats 
were injected by an IV bolus, at the onset of reperfusion. After reperfusion 
had continued for more than 1 hour, the chest was closed and animals were 
recovered from general anaesthesia and then returned to the animal facility. 
Following 21 days of reperfusion, i.e. 14 days after assesement of cardiac 
function, rats were anaesthetised using 5% isoflurane and then sacrificed by 
cervical dislocation. The hearts were then excised and perfused with 10ml 
of ice cold PBS, followed by 5ml ice cold 4% paraformaldehyde (Sigma) 
via an 18 Ch cannula inserted in the ascending aorta and then immersed for 
30 min in 4% paraformaldehyde on ice. Next the hearts were washed with 
PBS and incubated with 30% sucrose in PBS solution at 4°C overnight. 
Fixed hearts were then cut transversely into two segments between the base 
and apex. These segments were embedded in OCT compound (VWR) using 
a polyethylene mould and frozen in liquid nitrogen cooled isopentane and 
stored at -80°C. Cryosections (15-25μm) were cut from each segment using 
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a rotary cryotome (Leica) and then placed on polysine-coated glass slides 
(VWR), were washed with PBS and dried at room temperature overnight. 
The sections were then immersed in fast blue (0.15% Fast Blue in 
magnesium borate) for 10 min at room temperature, washed with de-ionised 
water, and stained with 0.1% picrosirius red F3B (0.1 g Sirus red in 100 ml 
saturated aqueous picric acid) for 10 min at room temperature. The sections 
were then rinsed in de-ionised water for 5 times and then immersed in picric 
alcohol (20 ml, absolute alcohol; 70 ml de-ionised water; 10 ml saturated 
aqueous picric acid). Sections were then dehydrated through a methanol 
series and mounted in DPX (VWR) and examined by light microscopy. 
 3.4.2 Results 
 A qualitative assessment of the post AMI collagen deposition was by 
cryosections of hearts stained with picrosirius red. Stained cryosections 
examined by light microscopy (Figure 3.4.2.1). When compared to the sham 
operated hearts, treatment by PBS upon reperfusion caused an extensive 
degree of extracellular collagen deposition within the infarct zone. Further, 
we noted the post infarct LV remodeling process by way of thinning and 
expansion of the infarct zone, LV cavity dilation, and hypertrophy of the LV 
zones remote from the infarct.  In contrast, hearts that had been subjected to 
ischaemia and reperfusion and treated with BMMNC upon reperfusion had 
a much reduced collagen deposition within the anterior LV and post infarct 
LV remodeling was much less. 
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Figure 3.4.2.1 Representative picrosirius red stained cryosections of hearts from 
animals 21 days post 25min LAD ischaemia and reperfusion. When compared to PBS, a 
single IV bolus of 10million BMMNC upon reperfusion had lower collagen deposition. The 
sham underwent the same surgical procedure except for LAD ischaemia and reperfusion. 
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3.5  Discussion 
 I have presented data investigating whether systemic IV BMMNC 
therapy can protect the ischaemic myocardium from reperfusion injury. 
Firstly, IV BMMNC upon reperfusion achieved significant reductions in 
myocardial infarct size, which are comparable to the powerful and innate 
cardioprotective mechanism IPC. Secondly, in a recovery model of regional 
myocardial ischaemia and reperfusion (I/R-7D), IV BMMNC upon 
reperfusion also preserved systolic and diastolic function. Consistent with 
the preservation in cardiac function, I also report that IV BMMNC upon 
reperfusion prevented post infarct fibrosis and the associated adverse left 
ventricular remodeling.  
 Previously, studies had suggested that the plasticity of 
haematopoietic stem/progenitor cells might attenuate myocardial infarction 
by de novo myocardial regeneration of an infarcted myocardium. Thus, 
these studies sought to exploit the plasticity of engrafted haematopoietic 
stem/progenitor cell to undergo subsequent transdifferentiation. To 
encourage this event, investigators injected highly enriched haematopoietic 
stem/progenitor (CD34+/C-kit+) cells into non-reperfusing ischaemic 
myocardium (Kocher et al., 2001; Orlic et al., 2001). The landmark study 
by Orlic et al., demonstrated that highly enriched syngeneic murine 
BMMNC (c-kit+/lin-) transdifferentiated to form a neo-vascularised and 
functional myocardium.  Stem cell injection into the infarct border zone was 
followed by stem cell recruitment into the necrotic region for putative 
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regeneration of the transmural murine infarct, which was reported to be 
around 68%. This infarct regeneration was associated with significant 
improvements in the systolic (~40%) and diastolic function (~36%). 
Interestingly, the same group also reported in a separate study that injections 
of granulocyte-colony stimulating factor (G-CSF) and stem cell factor 
(SCF) increased circulating haematopoietic stem/progenitor cells (c-kit + 
lineage -), which had the effect of significantly decreasing subsequent 
myocardial infarction (40%), LV dilation (26%), and diastolic stress (70%).  
More interestingly, Kocher et al., demonstrated that IV injection of 2x106 
G-CSF mobilized ex vivo human BMMNCs were cardioprotective when 
injected 48 h following LAD ligation in a rat model of AMI.  The donor 
human BMMNCs, that had been enriched for CD34+c-kit+ (>98% purity), 
were shown to immediately home into the infarct zone to subsequently 
stimulate neoangiogenesis, attenuate cardiomyocyte apoptosis, reduce LV 
collagen deposition, and improve cardiac function. I have presented data 
from experiments that did not use an enriched population of HSCs to protect 
against reperfusion injury of the ischaemic heart. Further, cell injection was 
by a single IV bolus at the onset of the reperfusing ischaemic myocardium 
i.e. a potentially hostile environment. These data suggest that the injected 
donor BMMNC could attenuate reperfusion-induced injury by a mechanism 
that was not entirely dependent upon donor cell plasticity. The data also 
suggest that pathophysiology for the reperfusion injury might be considered 
 
 
101 
 
separate from that of the injury due to ischaemia alone, as previously 
suggested (Hearse 1977; Vanden Hoek et al., 1996). 
The pathophysiology suggests that myocardial ischaemia and 
reperfusion injury is associated with two distinct modes of cell death, which 
are necrosis and apoptosis (Gottlieb et al., 1999). Necrosis is an energy 
independent or passive process where lack of ATP decreases 
Na+/K+/ATPase ionic pump activity, which leads to accumulation of intra-
cellular Na+ ions, massive cell swelling, and eventual loss of membrane 
integrity. The consequential cell membrane disruption releases intra-cellular 
proteins and explains the acute inflammation reaction that is associated with 
tissue necrosis.  Apoptosis, on the other hand, is a controlled energy 
dependent or active process which is observed to cause and organized 
degradation of nuclear and cytosolic contents, notably chromatin 
condensation, DNA fragmentation and apoptotic body formation. There is 
no cell membrane disruption and no acute inflammatory reaction (Fiers et 
al., 1999). It would therefore not be unreasonable to suggest that necrosis is 
the predominant mode of cell death during ischaemia when ATP levels are 
diminished (Kajstura et al., 1996) and that apoptosis is the predominant 
mode of cell death during reperfusion where ATP levels are normalizing 
(Zhao et al., 2000). This simplistic separation of necrotic-ischaemia and 
apoptotic-reperfusion is, however, controversial and a number of studies 
suggest that cellular attrition throughout ischaemia and reperfusion is 
entirely by necrosis (Buja et al., 1998; Ohno et al., 1998; Taimor et al., 
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1999). Most studies, however, suggest that bothe necrosis and apoptosis 
occur during ischaemia and the onset of reperfusion causes apoptosis to 
accelerate much faster than necrosis (Fliss et al., 1996; Freude et al., 2000; 
Gottlieb et al., 1994; Holly et al., 1999; Leist et al., 1997; Mocanu et al., 
2000; Scarabelli et al., 1999; Yaoita et al., 1998; Zhao et al., 2003; Zhao et 
al., 2001). Thus, a potential therapeutic strategy to attenuate ischaemia and 
reperfusion injury would be to target the reperfusion component which is 
suggested to contribute approximately 50% of the total AMI (Yellon et al., 
2007).  Hence, it has been shown that inhibition of apoptosis during 
reperfusion was associated with reduced infarct size and improved 
contractile function (Holly et al., 1999; Mocanu et al., 2000; Yaoita et al., 
1998; Zhao et al., 2003). Intriguingly, the data I have presented suggests 
that the hitherto perceived role for stem cell therapy, i.e. only to regenerate 
dead myocardium might be additional to preventing its death in the first 
instance.  
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Chapter 4 
Molecular Mechansisms Underlying Bone 
Marrow Mononuclear Cell Therapy and 
Attenuation of Regional Myocardial I/R Injury 
4.1 Introduction 
 In the previous chapter, I have presented data suggesting that systemic 
IV BMMNC is cardioprotective when injected at the onset of reperfusion, in 
a rat model of regional myocardial transient ischaemia and reperfusion 
injury. The timing of cell injection suggests the injected cells may have 
migrated to the ischaemic myocardium along an SDF-1 gradient exposed to 
the peripheral circulation at the onset of reperfusion (Askari et al., 2003). 
Notably, the clinical trials delivered autologous BMMNC after 24 h of 
reperfusion had elapsed, to prevent stem cell attrition in a hostile 
reperfusing myocardium (Chen et al., 2004; Janssens et al., 2006; Lunde et 
al., 2006; Meyer et al., 2006; Schachinger et al., 2006). If indeed the 
injected BMMNC homing to the reperfusing myocardium do not survive, it 
is then conceivable that these cells might have a non-regenerative beneficial 
role for protecting the myocardium from I/R injury. Thus, in this chapter, 
my aim was to elucidate the molecular mechanisms that might be 
contributory to the putative non-regenerative benefits of the BMMNC 
therapy. Firstly, I investigated whether BMMNC attenuated cardiomyocyte 
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apoptosis or necrosis or both. Secondly, I investigated whether BMMNC 
secreted factors that might be contributing to the cardioprotection. Finally, I 
investigated any changes to the myocardial proteome brought about by 
BMMNC therapy. 
4.2 Cardiomyocyte Apoptosis and Necrosis following  
BMMNC Therapy upon Reperfusion in Regional I/R 
Injury 
4.2.1 Methods 
BMMNC were isolated from ex vivo adult BM removed from the 
femurs and tibae of Wistar male rats, as described in chapter 2. Randomly 
selected Wistar male rats were subjected I/R-2h, as described. BMMNC 
delivery was by single IV injection at onset of reperfusion or at later time 
points during reperfusion. At the end of reperfusion, cardiomyocytes were 
isolated from the region of left ventricle (LV) that had been subjected to 
LAD ischaemia and reperfusion, the area at risk (ARR), as described in 
chapter 2 (Mitra et al., 1985). Cardiomyocyte staining for apoptosis and 
necrosis, for FACS flow cytometric analysis, was as described in chapter 2.  
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Table 4.2.1.1 Experimental Design: BMMNC post reperfusion in a 
model of 25 min LAD ischaemia and 2 h reperfusion. Wistar male rats 
underwent either 25 min LAD occlusion and 2 h  of LAD reperfusion (I/R-
2h) or no LAD occlusion i.e. sham procedure. The time of either PBS or an 
IV bolus of BMMNC was from 0 min to 90 min following onset of 
reperfusion. n is the number of animals in each group. 
 
Group n Protocol IV Injectate 
Time of Injection 
 Post Reperfusion 
 (min) 
Sham 5 No I/R-2h 0.5 ml PBS 0 
PBS 5 I/R-2h 0.5 ml PBS 0 
0 5 I/R-2h 10 x 106 BMMNC 0 
15 5 I/R-2h 10 x 106 BMMNC 15 
30 5 I/R-2h 10 x 106 BMMNC 30 
60 4 I/R-2h 10 x 106 BMMNC 60 
90 5 I/R-2h 10 x 106 BMMNC 90 
 
 
 
 
 
 
 
106 
 
4.2.2 Results 
In Figure 4.2.2.1(A), I have shown that the AAR (% LV), was 
similar between PBS (control) and treatment groups. In Figure 4.2.2.3, I 
have shown that the mean arterial pressure, heart rate and pressure rate 
index  were not different between groups at all time points (2-way ANOVA, 
P>0.05). In figure 4.2.2.2, when compared to the PBS  control group the AAR 
cardiomyocyte apoptosis was significantly reduced when BMMNC were 
injected within the first 30 min of reperfusion (0 min, 14 ± 3%; 15min, 15 ± 
2%; 30 min, 11 ± 1%; versus PBS 28 ± 3%; P<0.001). This was concordant 
with the AAR cardiomyocytes expressing  activated Caspase 9; i.e. when 
compared to PBS,  Caspase 9 activation was significantly lower when 
BMMNC were injected within the first 30 min of reperfusion (0 min, 13 ± 
3%; 15min, 16 ± 1%; 30 min, 16 ± 2%; versus PBS 31 ± 4%; 1-way 
ANOVA, Dunnett’s post test P<0.05).  In figure 4.2.2.1(B), when compared 
to the control group (PBS), cardiomyocyte necrosis was also significantly 
reduced when BMMNC were injected within the first 30 min of reperfusion  
(0 min, 5 ± 1%; 15 min, 8 ± 2%; 30 min, 8 ± 2%; versus PBS 16 ± 1%; 1-
way ANOVA, Dunnett’s post test P<0.05). Later injections of BMMNC, i.e. 
at 60 min and 90 min post onset of reperfusion, also attenuated 
cardiomyocyte apoptosis and necrosis upon injection, but these reductions 
did not reach statistical significance. 
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Figure 4.2.2.1 Area at risk (AAR) cardiomycyte necrosis detected by FACS flow 
cytometry (A) The AAR  of the left ventricle (LV) subjected to 25 min LAD ischaemia 
and 2 h LAD reperfusion and  expressed as % LV was similar between all groups (1-way 
ANOVA, P>0.05). (B) Compared to PBS, a single IV bolus of 10 million BMMNC at 
either 0 min, 15 min, or 30 min after the onset of reperfusion significantly reduced necrosis 
of cardiomyocytes isolated from the AAR (1-way ANOVA and Dunnett’s post hoc test (** 
P<0.01, * P<0.05). 
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Figure 4.2.2.2 Area at risk (AAR) cardiomycyte apoptosis and caspase 9 activation 
detected by FACS flow cytometry (A) compared to PBS, 10 million BMMNC at 0 min, 
15 min, or 30 min after the onset of reperfusion significantly reduced the number of 
apoptotic cardiomyocytes (1-way ANOVA and Dunnett’s post hoc test, ** P<0.01).(B) 
Compared to PBS, BMMNC at 0 min, 15 min, or 30 min at reperfusion significantly 
reduced the number of cardiomyocytes with activated Caspase 9 (1-way ANOVA and 
Dunnett’s post hoc test, ** P<0.01 and *P<0.05).  
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Figure 4.2.2.3 The haemodynamic parameters of animals subjected to 25 min LAD 
occlusion and 2 h LAD reperfusion were similar between all groups (A) Mean arterial 
pressure mmHg. (B) Heart rate (beats per minute). (C) Pressure rate index (PRI) the 
product of mean arterial pressure and heart rate (2-way ANOVA, P > 0.05). 
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4.3 Removal of Cells from BMMNC Therapy did Not 
Eliminate Cardioprotection 
4.3.1Methods  
 BMMNC were isolated from ex vivo adult BM aspirated from 
femurs and tibae of Wistar male rats, as previously described. Extracellular 
factors as secreted by BMMNC were collected by incubating the cells in 
PBS and the resulting BMS was obtained in various concentrations by 
incubating increasing numbers of BMMNC in 1ml PBS: 10, 20, 50 or 100 
million cells. The time of incubation was varied at either 2 h or 24 h in a cell 
culture incubator (5% CO2 and humidified air at 37°C; CB150, USA). Post 
incubation, cells were separated from the supernatant by centrifugation 
(13000 rpm) followed by filtration (0.2 µm sterile syringe filter, Corning 
Life Sciences, USA). The supernatant was used immediately after 
preparation. Animals that were randomly selected to receive BMS were 
administered 0.5 ml BMS as a single IV bolus, at the onset of LAD 
reperfusion. At the end of 2 h reperfusion, the region of the left ventricle 
subjected to LAD ischaemia and reperfusion was analyzed for infarct size 
by observers blinded to each treatment group. 
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   Table 4.3.1.1 Experimental Design:   BMMNC derived supernatant over 2 h (BMS-
2h) upon reperfusion in a model of 25 min LAD ischaemia and 2 h reperfusion. Wistar 
male rats underwent either 25 min LAD occlusion and 2 h  of LAD reperfusion (I/R-2h) or 
no LAD occlusion i.e. sham procedure. BMS-2h obtained by increasing numbers of 
BMMNC over an incubation time of 2 h after which BMMNC were removed from the 
supernatant. An IV bolus of either PBS or BMS-2h was at the onset of reperfusion. n is the 
number of animals in each group. 
Group N Protocol IV Injectate Number of BMMNC used to obtain BMS-2 h 
0 3 I/R-2h BMS-2h (0) 0  
10 3 I/R-2h BMS-2h (10) 10 x 106  
20 3 I/R-2h BMS-2h (20) 20 x 106  
50 3 I/R-2h BMS-2h (50) 50 x 106  
100 3 I/R-2h BMS-2h (100) 100 x 106  
 
 
Table 4.3.1.2 Experimental Design:   BMMNC derived supernatant over 24 h (BMS-
24h) upon reperfusion in a model of 25 min LAD ischaemia and 2 h reperfusion. 
Wistar male rats underwent either 25 min LAD occlusion and 2 h  of LAD reperfusion (I/R-
2h) or no LAD occlusion i.e. sham procedure. BMS-24h obtained by increasing numbers of 
BMMNC over an incubation time of 24 h after which BMMNC were removed from the 
supernatant. An IV bolus of either PBS or BMS-24h was at the onset of reperfusion. n is 
the number of animals in each group. 
Group n Protocol IV Injectate Number of BMMNC used to obtain BMS-24h 
0 7 I/R-2h BMS-24h (0) 0 
10 3 I/R-2h BMS-24h (10) 10 x 106 
20 6 I/R-2h BMS-24h (20) 20 x 106 
50 5 I/R-2h BMS-24h (50) 50 x 106 
100 4 I/R-2h BMS-24h (100) 100 x 106 
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4.3.2 Results 
 In Figure 4.3.2.1 (A), I have presented the AAR (% of LV) and this 
was similar between controls and treatment groups (1-way ANOVA, 
P>0.05). In Figure 4.3.2.3, I have presented the data for the haemodynamic 
parameters of mean arterial pressure, heart rate and pressure rate index. 
They were similar between all groups and at all time points (2-way 
ANOVA, P>0.05). In Figure 4.3.2.1 (B), I have presented the infarct size data 
and when compared to the control group (PBS), IV injection of BMS derived 
after 2 h of incubation did cause non-significant reductions in infarct size, 
despite increasing the number of BMMNC numbers used to obtain BMS.  
 In Figure 4.3.2.2 (B), in contrast, when compared to the PBS group, 
BMS derived after 24 h cell incubation caused greater reductions in the 
infarct size, which achieved statistical significance when BMS was obtained 
from at least 20 million BMMNC  (PBS 57 ± 4 % versus BMS-20, 35 ± 3 
%; 1-way ANOVA and Dunnett’s post test, P < 0.01). Maximal attenuation 
of the LV infarct size was notable where BMS was from 50 million or more 
BMMNC. Thus, removing the cells from BMS did not eliminate 
cardioprotection; however, equivalent cardioprotection was only achieved 
when BMS had been obtained after a 24 h incubation with BMMNC that 
were double in number (or greater) to that required for cell therapy.  
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Figure 4.3.2.1 Infarct size and cell-free supernatant (BMS-2h) from BMMNC after 2 h 
incubation (A) The area at risk (AAR) from 25 min LAD ischaemia and 2 h LAD 
reperfusion, (% LV) was similar between all groups (1-way ANOVA, P>0.05). (B) When 
compared to the PBS, infarct size was non-significantly reduced by a single IV bolus of 
BMS-2h despite increasing the BMMMC number to obtain BMS-2h (1-way ANOVA, 
P>0.05). 
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Figure 4.3.2.2 Infarct size and cell-free supernatant (BMS-24h) after 24 h incubation 
of BMMC (A) The area at risk (AAR) from 25 min LAD ischaemia and 2 h LAD 
reperfusion, expressed as % LV was similar between all groups (1-way ANOVA, P>0.05). 
(B)When compared to the PBS, infarct size was reduced by a single IV bolus of BMS-24h 
and this reduction was statistically significant for BMS-24h from 20 million or more 
BMMNC (1-way ANOVA and Dunnett’s post test, *P < 0.01, n=6). 
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Figure 4.3.2.3  Haemodynamic variability and cell-free supernatant (BMS-24h) from 
BMMNC after 24 h incubation. When compared with PBS (control) alterations in (A) 
mean arterial pressure (MAP), (B) heart rate (HR), and (C) pressure rate index (PRI) were 
similar between all experimental groups (2-way ANOVA, P > 0.05). 
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4.4 Modulation of the Left Ventricular Proteome by 
BMMNC or BMS Therapy post Regional I/R 
4.4.1 Methods 
 BMMNC were isolated from ex vivo adult BM aspirated from 
femurs and tibae of Wistar male rats, as previously described. Randomly 
selected Wistar male rats underwent 25 min LAD ischemia and 2 h of 
reperfusion. Animals received either 10 million BMMNC or BMS obtained 
from 50 million cells over 24 h.  Administration was by a single IV bolus at 
the onset of reperfusion and control animals received PBS. Sham controls 
underwent the same surgical manipulation but not LAD ischaemia and 
reperfusion. At the end of reperfusion, the ex vivo left ventricular area at risk 
(AAR) was rapidly cooled by immersion in liquid nitrogen and stored in a 
freezer (-80°C) for subsequent proteomic analysis, as described in methods 
(chapter 2).  
  4.4.2 Results 
 Gel image analysis of triplicate 2-DE gels for each experimental 
group revealed 464 matched protein spots between the four experimental 
groups (Figure 4.4.2.1). When comparing the spot intensities of matched 
spots, 87 spots had differences between the experimental groups.When 
comparing protein expression of PBS controls, hearts treated with either 
BMMNC or BMS demonstrated significantly higher expression of a number 
of proteins which are shown in Table 4.4.2.2 
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Specifically, when compared to sham hearts, the expression of anti-
apoptotic signal transduction protein 14-3-3 epsilon was 1.5 fold lower in 
PBS treated hearts.  In contrast, both BMMNC and BMS treated hearts 
demonstrated a 1.5 fold higher expression of the anti-apoptotic signal 
transduction protein 14-3-3 epsilon when compared with PBS treated 
control hearts.  When compared to sham hearts, the expression of the 
antioxidant peroxiredoxin-6 was 2.3 fold lower in PBS treated hearts.  The 
expression of the other differentially expressed antioxidant catalase was 
similar, when comparing the PBS and sham treated hearts. The expression 
of both antioxidants catalase and peroxiredoxin-6 was at least two folds 
higher in the BMMNC treated hearts than in the PBS hearts, whilst only the 
expression of peroxiredoxin-6   was 1.6 fold higher for the BMS treated 
hearts than in the PBS hearts. Turning to the expression of heat shock 
protein (HSP), when compared to sham hearts, the expression of HSPs was 
lower in PBS treated hearts for both the low and the high molecular weight 
HSPs. Conversely, compared to the PBS control, BMMNC treated hearts 
had increased expression of HSP 20 (3.0 folds), alpha-B-crystallin (1.7 
folds), HSP 72 (2.8 folds), TNF-Receptor Associated Protein-1 (2.3 folds), 
and Ischaemia Responsive Protein-94 (1.6).  This trend of higher HSP 
expression was also demonstrated when comparing PBS controls with the 
BMS treated animals, however, this was noted for only three HSP, namely 
alpha-B-crystallin (1.5 folds), HSP 72 (2.1 folds), TNF, and Ischaemia 
Responsive Protein-94 (1.5).  
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There were also changes in the expression of cytosolic and 
mitochondrial bioenergetic proteins; when compared with the sham hearts, 
PBS treated hearts had lower expression of alpha-Enolase (2.3 folds). 
Conversely, on comparing the PBS control hearts, BMMNC hearts had 
higher expression of alpha-Enolase (1.6 folds) and Glyceraldehyde-3-
Phosphate Dehydrogenase (2.3 folds). Similarly, comparing the BMS 
treated hearts also showed a trend for increased expression of glycolytic 
proteins by the higher expression of Glyceraldehyde-3-phosphate 
dehydrogenase (1.8 folds). The expression of fatty acid oxidation proteins 
was remarkably different to that noted for the glycolytic proteins. When 
compared with the sham-operated hearts, the PBS treated hearts’ expression 
of acyl-co-A reductases and carboxylase was slightly higher. In sharp 
contrast, treatment with BMMNC caused the hearts to have a lower 
expression of acyl-co-A reductases and carboxylase. The trend for reduced 
expression of fatty acid acyl-co-A reductases and carboxylase expression 
was also apparent in the BMS treated hearts. There was attenuation of 
mitochondrial respiratory protein expression in the PBS treated hearts 
attenuated, when compared to the sham hearts: aconitase (3.4 folds) and 
voltage dependent anion channel protein-1 (1.5 fold). Whilst there was 
increased expression of these proteins in the both the BMMNC and the 
BMS treated hearts. Interestingly glutamate dehydrogenase expression was 
unchanged in PBS hearts but significantly decreased in both the BMMNC 
and the BMS treated hearts.  
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Figure 4.4.2.1 The 2-dimension gel electrophoresis images showing protein separation 
of protein homogenates from the left ventricular area at risk. Protein homogenates 
were derived from area at risk of hearts subjected to 25 min LAD ischemia followed by 2 h 
reperfusion or sham animals (no LAD ischaemia and reperfusion).  
 
 
 
Sham PBS
BMMNC BMS-24h
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 Table 4.4.2.2 Differential protein expression as analyzed by proteomics of the left 
ventricular area at risk post 25 min LAD ischaemia and 2h reperfusion. The group 
comparisons were: (1) PBS versus sham;  (2) BMMNC versus PBS; (3) Supernatant from 
50 million BMMNC after 24 h (BMS) versus PBS. Protein spots with significant folds 
increase (↑) or decrease (↓) underwent analysis by mass spectroscopy to identify each 
protein by number of peptides matched, the total percentage of peptide sequence coverage, 
and the corresponding Mascot score. A Mascot score of greater than 30 suggests protein 
identification with a statistical significance of P< 0.05. Mr was the observed molecular 
weight (Daltons) and pI denotes isoelectric pH. 
Protein Role 
PBS 
versus 
Sham 
(folds) 
BMMNC 
versus 
PBS 
(folds)
BMS 
versus 
PBS 
(folds)
Mascot 
Score Mr pI 
Peptides 
Matched 
% Total 
Sequence 
Coverage 
14-3-3 epsilon Signaling ↓ (1.5) ↑ (1.5) ↑ (1.5) 489 29274 4.5 12 41 
Peroxiredoxin-6 Antioxidant ↓ (2.3) ↑ (2.1) ↑ (1.6) 351 24672 6.5 5 27 
Catalase Antioxidant ↑ (1.2) ↑ (2.6) ↓ (1.1) 193 59931 7.15 4 8 
HSP 20 HSP ↓ (13) ↑ (3) ↓ (1.3) 93 17551 6.05 3 19 
Alpha 
 B-crystallin HSP ↓ (3.0) ↑ (1.7) ↑ (1.5) 207 20155 6.84 6 29 
HSP 72 HSP ↓ (4.3) ↑ (2.8) ↑ (2.1) 261 71055 5.37 6 12 
TNF-Receptor 
Associated 
Protein 1 
HSP ↓ (2.7) ↑ (2.3) ↑ (1.3) 321 80639 6.56 7 12 
Ischaemia 
Responsive 
Protein-94 
HSP ↓ (1.6) ↑ (1.6) ↑ (1.5) 166 94795 5.13 4 5 
Alpha-enolase Glycolysis ↓ (2.3) ↑ (1.6) 1.0 717 47309 6.16 15 38 
Glyceraldehyde 
3-Phosphate 
Dehydrogenase 
Glycolysis 1.0 ↑ (2.3) ↑(1.8) 170 36098 8.43 4 11 
Aconitase Mitochondrial 
Respiratory ↓ (3.4) ↑ (4.7) ↑(4.3) 398 86162 7.87 12 17 
Citrate synthase Mitochondrial 
Respiratory ↑ (1.1) ↑ (2.3) ↓(1.7) 132 52176 8.53 5 11 
Voltage 
Dependent 
Anion Channel 
Protein 1 
Mitochondrial 
Respiratory ↓ (1.5) ↑ (2.7) ↑(1.8) 308 30720 8.63 5 19 
 
 
121 
 
4.5 BMMNC Therapy and Cell Signaling 
4.5.1 Methods 
Having shown that both BMMNC and the BMMNC derived 
supernatant, (BMS) were equally cardioprotective, in a rat model of LAD 
regional ischaemia and myocardial reperfusion, I investigated the signaling 
pathways for BMMNC mediated cardioprotection. The increased expression 
of 14-3-3 epsilon by both BMMNC and BMS treated hearts suggested that 
PI3K/Akt survival kinase pathway might have a role in BMMNC mediated 
cardioprotection. Phosphorylation of BAD by Akt causes it to bind to 14-3-
3 epsilon instead of the anti-apoptotic proteins Bcl-2 and Bcl-XL (Zha et al., 
1996). Thus, PI3K/Akt signaling was investigated. 
BMMNC were isolated from ex vivo adult BM aspirated from 
femurs and tibae of Wistar male rats, as previously described. Infarct size 
was measured in randomly selected  Wistar male rats that had been treated 
with the PI3K inhibitor LY294002 (0.3mg/ kg), by slow IV infusion 10 min 
prior to 25 min LAD ischaemia and 2 h reperfusion (Table 4.5.1).  
In order to detect PI3K/Akt signaling, randomly selected Wistar 
male rats underwent 25 min LAD ischemia and only 30 min of reperfusion. 
Animals received 10 million BMMNC by single IV bolus at the onset of 
reperfusion and control animals received PBS. Sham controls underwent the 
same surgical manipulation but not LAD ischaemia and reperfusion (Tables 
4.5.1.1 & 2). At the end of reperfusion, the left ventricular area at risk 
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(AAR) was rapidly cooled by immediate immersion in liquid nitrogen and 
storage in a deep freezer at -80°C for subsequent western blot analysis, as 
described in methods (chapter 2). Western blots of protein extracts from 
AAR protein homogenates were analyzed for phosphorylation of Akt, GSK-
3, p38 MAPK and NF-κB. Precise details of the western blotting 
techniques are given in Chapter 2.   
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Table 4.5.1.1 Experimental Design: Infarct size and pre-treatment with LY294002 and 
injection of IV BMMNC upon reperfusion in a model of 25 min LAD ischaemia and 2 
h reperfusion (I/R-2h). Wistar male rats pretreatment with LY294002 (0.3mg/kg, IV) 10 
min prior to the onset of either I/R-2h or no LAD occlusion i.e. sham procedure. Either 
PBS or a bolus of 10 million BMMNC was at onset of reperfusion. n is the number of 
animals in each group. 
Group n Protocol Pre-Ischaemia Injectate Reperfusion 
Injectate 
Sham  5 No I/R-2h LY294002 (0.3 mg/ kg) PBS (0.5 ml) 
PBS  6 I/R-2h LY294002 (0.3 mg/ kg) PBS (0.5 ml) 
BMMNC 6 I/R-2h LY294002 (0.3 mg/ kg) BMMNC (10 x 106) 
 
 
Table 4.5.1.2 Experimental Design: Cell signaling analysis following pre-treatment 
with either LY294002 (0.3mg/kg) or dimethyl sulphoxide (DMSO) 10% in a model of 
25 min LAD ischaemia and 30 min reperfusion (I/R-30min). Wistar male rats were 
pretreated with either DMSO 10% (vehicle) or LY294002 (0.3 mg/kg, IV) 10 min prior to 
the onset of either I/R-30min or sham procedure. Either PBS or a bolus of 10 million 
BMMNC were given  upon reperfusion and  n is the number of animals in each group. 
Group n Protocol 
Injectate 
Pre-Ischaemia 
Injectate Upon 
Reperfusion 
Sham  5 No I/R-30min DMSO 10% PBS 
PBS 5 I/R-30min DMSO 10% PBS 
LY294002 + PBS  6 I/R-30min LY294002  PBS 
BMMNC 3 I/R-30min LY294002 BMMNC (10 x 106) 
LY294002 + 
BMMNC 
3 I/R-30min LY294002  BMMNC (10 x 106) 
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4.5.2 Results 
 When compared with controls, pre-ischaemia treatment with 
LY294002 and regional myocardial ischaemia-reperfusion injury (I/R) 
caused a significant myocardial infarct; the injection of BMMNC upon 
reperfusion could not attenuate the size of infarction (Figure 4.5.2.1 B). 
There was no difference between groups when comparing the AAR and the 
haemodynamic parameters (Figures 4.5.2.1 A & 4.5.2.2). 
 When compared to the PBS controls, BMMNC injection upon 
reperfusion caused significant Aktserine473 phosphorylation and pre-ischaemia 
treatment with LY294002 ameliorated BMMNC mediated Aktserine473 
phosphorylation (Figure 4.5.2.3). When compared to the PBS controls, 
BMMNC injection upon reperfusion caused significant GSK-3βserine9 
phosphorylation and pre-ischaemia treatment with LY294002 ameliorated 
BMMNC mediated GSK-3βserine9 phosphorylation. Conversely, compared to 
the PBS controls, BMMNC injection upon reperfusion caused significant 
reductions in both the phosphorylation of p38-MAPK and nuclear 
translocation of NF-κB. Thus, pre-ischaemia treatment with LY294002 
ameliorated BMMNC mediated inhibition of both p38-MAPK and NF-κB 
(Figure 4.5.2.4). 
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Figure 4.5.2.1 Infarct size and pre-treatment with LY294002 (A) The area at risk 
(AAR) from 25 min LAD ischaemia and 2 h LAD reperfusion was with LY294002 
(0.3mg/kg). When compared to PBS, infarct size was similar to the group receiving a single 
IV bolus of 10 BMMNC upon reperfusion  (1-way ANOVA and Dunnett’s post test, 
P>0.05, n=6).  
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Figure 4.5.2.2 The haemodynamic parameters were similar between all experimental 
groups from baseline to the end of each experiment. (A) Mean arterial pressure (MAP); (B) 
Heart rate (HR); (C) Pressure rate index (PRI) (2-way ANOVA, P > 0.05). 
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Figure 4.5.2.3 Western blots of left ventricular area at risk 30 min post LAD 
reperfusion to detect phosphorylated cytosolic Akt and glycogen synthase kinase-
3β(GSK-3β). (A) When compared with phosphate buffered saline (PBS), an IV bolus of 10 
million bone marrow mononuclear cells (BMMNC) upon reperfusion significantly 
augmented the phosphorylation of Akt at serine 473. Akt phosphorylation is significantly 
lower following pre-treatment with LY294002. (B)  Compared to PBS, BMMNC upon 
reperfusion also significantly phosphorylated GSK-3β at serine 9, which was significantly 
lower following pre-treatment with LY294002. 1-way ANOVA and Dunnett’s post test; 
**P<0.01 and *P< 0.05. 
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Figure 4.5.2.4 Western blots of left ventricular area at risk 30 min post LAD 
reperfusion to detect phosphorylated cytosolic p38-mitogen activated protein kinase 
(p38MAPK) and nuclear translocation of p65 nuclear factor (p65NF-κB). (A) When 
compared with phosphate buffered saline (PBS), an IV bolus of 10 million bone marrow 
mononuclear cells (BMMNC) upon reperfusion significantly attenuated the 
phosphorylation of p38MAPK. Significantly, phosphorylation of p38 MAPK was higher 
following pre-treatment with LY294002. (B)  Compared to PBS, BMMNC upon 
reperfusion also significantly attenuated nuclear translocation of p65NF-κB, which was 
significantly higher following pre-treatment with LY294002 (1-way ANOVA and 
Dunnett’s post hoc test, *P< 0.05). 
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4.6 Discussion 
In this chapter, I have shown that in a rat model of regional I/R, IV 
administration of either BMMNC or BMS upon reperfusion reduced infarct 
size. Further, BMMNC and BMS were associated with increased expression 
of cardioprotective proteins.  That cardioprotection was not exclusive to 
injection of cells suggested that BMMNC afforded cardioprotection by 
secreted factors. The equivalent expression of the anti-apoptotic signaling 
protein 14-3-3 epsilon by both BMMNC and BMS suggests the extracellular 
pro-survival factors activated either G-protein coupled receptors or receptor 
tyrosine kinases to activate the PI3K/Akt survival kinase pathway. 
Activated PI3K converts membrane phosphatidylinositol 4, 5 diphosphate 
(PIP2) to phosphatidylinositol 3,4,5 triphosphate (PIP3). Akt binds to PIP3 
and is brought into close proximity with membrane bound phosphoinositide 
dependent kinases (PDK1 and PDK2). PDK2 phosphorylates Akt at serine-
473, which then stimulates the phosphorylation of Akt at threonine-308 by 
PDK1 to fully activate Akt (Sarbassov et al., 2005). Activated Akt 
phosphorylates and inactivates a myriad of pro-apoptotic molecules 
including Bcl-2-associated death promoter protein (BAD). Serine 
phosphorylation of BAD by Akt, permits 14-3-3 epsilon to bind with BAD, 
and prevents BAD from forming hetero-dimers with the anti-apoptotic 
proteins Bcl-2 and Bcl-XL (Zha et al., 1996). Free Bcl-2 and Bcl-XL 
normally bind to mitochondrial voltage dependent anion channel (VDAC) to 
maintain the channel in a controlled open state, which allows continued 
 
 
130 
 
export of high energy phosphates (Vander Heiden et al., 2000). 
Dimerization of Bcl-2 or Bcl-XL with BAD, frees the pro-apoptotic Bax and 
Bak to bind with VDAC causing its disruption, mitochondrial 
depolarization, release of cytochrome c, and subsequent initiation of 
apoptosis (Shimizu et al., 1999). Thus, the higher expression of 14-3-3 
epsilon in the BMMNC and BMS treated hearts may have contributed to the 
increased expression of voltage dependent anion channel isoform 1 (VDAC-
1). Moreover, VDAC-1 may have a role in the formation of mitochondrial 
membrane transition pore (MPTP) pore (Cesura et al., 2003; Crompton et 
al., 1998). Thus, the higher expression of  VDAC-1 during reperfusion 
could have prevented the formation of the MPTP, subsequent mitochondrial 
membrane depolarization, and release of pro-apoptotic proteins (Halestrap 
et al., 2004).  
The treatment with BMMNC upon reperfusion was also associated with 
significant attenuation in phosphorylated p38 MAPK. Activated or 
phosphorylated p38 MAPK augments myocardial I/R injury (Gao et al., 
2002; Kaiser et al., 2004) possibly by MAPK mediated phosphorylation of 
NHE-1 during reperfusion(Khaled et al., 2001). But pre-treatment with 
LY294002 only partially restored phosphorylated p38 MAPK, when 
compared with the controls (Figure 4.5.4). This suggests that BMMNC 
inhibition of p38 MAPK during I/R might  also be by other mechanisms 
such as ROS as suggested a previous report (Sabri et al., 1998). Thus, 
BMMNC may have also attenuated the phosphorylation of p38 MAPK by 
 
 
131 
 
attenuating ROS possibly by BMMNC expressed anti-oxidants, which is  
corroborated by their higher expression as shown in the proteomic data. 
The increased expression of the anti-oxidants catalase and 
peroxiredoxin-6, in hearts treated by BMMNC may have contributed to their 
cardioprotective role (Nagy et al., 2006). Interestingly, in the BMS treated 
hearts there was only increased expression of peroxiredoxin-6. The 
traditional role for anti-oxidants as scavengers of ROS has, however, 
recently been revised as it becomes more evident that ROS play an 
important regulatory role in pro-survival signaling pathways. Intracellular 
H2O2 can reversibly oxidize and inhibit the lipid phosphatase PTEN 
(phosphatase and tensin deleted in chromosome 10), which 
dephosphorylates PIP3 and blocks the phosphorylation of Akt. Previous 
reports have suggested that some growth factors increase pro-survival 
signaling by increased intracellular H2O2 production and inhibition of PTEN 
(Kang et al., 2004). The presented data suggests that excessive antioxidants 
may be unnecessary and that PI3 mediated Akt signaling is of much greater 
importance for attenuating I/Rinjury.   
Further aspects of BMMNC mediated cardioprotection that were 
enlightened by the proteomic data need further discussion. HSPs have 
important roles as molecular chaperones by ensuring correct folding of 
newly synthesized proteins and repair or degradation of denatured proteins. 
Both BMMNC and BMS treated hearts had had increased expression of 
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HSP which have been suggested to protect against I/R injury: HSP20 (Fan 
et al., 2005), alpha-B-crystallin (Morrison et al., 2003), HSP72 (Suzuki et 
al., 2002), TNF receptor associated protein-1(Montesano Gesualdi et al., 
2007; Xiang et al., 2010), and ischemia responsive protein-94 (Yagita et al., 
1999).  The regulation of HSP is by Heat Shock Transcription factor-1, 
which is subject to PI3K/Akt signaling (Zhou et al., 2004). 
Increased glycolytic bioenergetics is associated with reduced fatty acid 
oxidation and this bioenergetic switch reportedly can reduce apoptosis 
following myocardial ischemia and reperfusion (Opie et al., 2002).  This 
was particularly notable in BMMNC treated hearts and to some extent in 
BMS treated hearts. Fatty acid oxidation during reperfusion leads to lipid 
peroxidation and loss of mitochondrial cardiolipin, which is associated with 
leakage of cytochrome c from the inner mitochondrial membrane with 
subsequent initiation of apoptotic cell death (Paradies et al., 2004). The 
cytoprotective metabolic switch from FAO to glycolysis  by the pro-survival 
transcription factor, hypoxia inducible factor-1-alpha (HIF-1α). Effects of 
HIF-1α include the increased expression of glycolytic enzymes and 
suppression of fatty acid oxidation enzymes (Belanger et al., 2007). During 
hypoxia, HIF-1α levels increase and undergo nuclear translocation, to 
promote transcription of pro-survival genes.  Stabilization of HIF-1α during 
reperfusion is dependent upon activation of PI3/Akt and the concomitant 
increased expression of HSP72 and HSP90. Both HSP72 and HSP90 bind to 
the oxygen dependent degradation domain of HIF-1α and prevent its 
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degradation during normoxia (Zhou et al., 2004). This is concordant with 
the data presented here. 
There are a number of limitations to the data presented in this chapter. 
Firstly, we were not able to identify or characterise the cardioprotective 
composition of BMS. An attempt to separate and identify proteins in BMS 
by proteomics, however, produce 2-DE gel images of very low intensity 
spots and protein identification was not possible. Secondly, the 
intravenously injected BMMNC were not tracked to see whether they 
homed into the ischemic myocardium or became trapped in the other organs 
such as the lung. Thus, it is not entirely clear whether the injected BMMNC 
caused a local effect, a distant effect, or a combination of both.  
In summary, I/R can be attenuated by IV administration of either 
BMMNC or BMS at the onset of reperfusion. This suggests adult stem cells 
have an important non-regenerative cardioprotective role which is mediated 
by their secreted factors. Moreover, the injection of BMMNC or BMS was 
associated with increased expression of cardioprotective proteins including 
proteins associated with PI3/Akt signaling, anti-oxidants, HSP and 
glycolytic proteins. The data presented here suggests that the secreted 
proteins of adult stem cells may be used as adjuncts to current myocardial 
protective strategies and could augment myocardial protection.  Further, 
BMS may provide an “off the shelf” therapeutic option and warrants further 
investigation. 
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Chapter 5 
Mesenchymal Stem Cell Therapy and Regional 
Myocardial I/R 
 5.1 Introduction 
 In the previous chapter, the data supported the hypothesis that non-
regenerative mechanisms principally underlie cardioprotection afforded by 
unfractionated BMMNC therapy. Unfractionated BMMNC, however, 
contain three types of stem cells: haematopoietic stem cells, MSCs, and 
endothelial progenitor stem cells . Mesenchymal stem cells contribute only a 
small fraction of the total BMMNC population (< 0.01%) and are 
considered to be the stem cells to regenerate non-haematopoietic tissues 
(Prockop 1997). Mesenchymal stem cells are easily isolated from BM by 
their adherence to plastic. Mesenchymal stem cells are highly proliferative 
and can be rapidly expanded in culture, have potential for safe allogeneic 
cell therapy, and also have potential to differentiate into non-haematopoietic 
cells (Ferrari et al., 1998; Friedenstein et al., 1987; Makino et al., 1999). 
These advantages suggest important benefits that have not been 
demonstrated in the clinical trials to date (1) allogeneic transplantation of 
superior quality to autologous stem cells, (2) ease of isolation and high 
proliferative activity may permit “off the shelf” stem cell therapy (3) 
cardiomyocyte differentiation to replace dead or injured cardiomyocytes. 
With these advantages in mind, I investigated whether bone marrow derived 
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MSC might be cardioprotective in a rat model of LAD myocardial 
ischaemia and reperfusion.  
5.2 Mesenchymal Stem Cell Therapy and Regional 
Myocardial I/R 
5.2.1 Methods 
 Donor MSC were isolated from BM obtained from ex vivo femurs 
and tibae of Wistar male rats. Whole bone marrow was collected in 
complete culture media (10ml alpha-Modified Eagles Medium (α-MEM) + 
1% glutamine + penicillin 100U/ml + streptomycin 100mg/ml, and 5% 
foetal bovine serum) and MSC were isolated by virtue of their adherence to 
a plastic surface (Friedenstein et al., 1987). The BM obtained from femurs 
and tibae was centrifuged (1500rpm for 5 min) and resuspended in culture 
medium for subsequent culture in T75 tissue culture flasks. Non-adherent 
cell were removed by repeat washes with culture media at the following 
times 1, 2, 6, 12, 24, 48 and 72 h. The remaining plastic adherent cells had 
media changes every 48 h and passage at 70% confluence by 0.25% trypsin-
EDTA for 5 min in a 37oC incubator with 5% CO2. At each passage, 
reseeding cell density was 1.5x105/cm2. Culture expansion of plastic 
adherent cells was demonstrable beyond passage number 25, however, only 
cells obtained from cultures less than passage number 13 were used for in 
vivo experimentation. The isolated and culture expanded cells were 
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characterised at each passage by flow cytometric analysis for specific cell 
surface antigens as previously described (Chapter 2). Following culture 
expansion cells were mobilised: removal of the culture medium and 
incubation with 5ml 0.25% trypsin-EDTA for 5 min in a 37oC incubator 
with 5% CO2. The disassociated cells were collected in 1 ml Hank's 
Buffered Salt Solution (HBSS), centrifuged at 1500 rpm for 5 min, and 
resuspended in 0.5 ml PBS. logarithmic amplification.  
 Randomly selected Wistar male rats underwent 25 min LAD 
ischemia and 2 h reperfusion. At the onset of reperfusion, animals selectec 
for MSC therapy received MSC, suspended in 0.5 ml PBS, as a single IV 
bolus. At the end of 2 h reperfusion, the region of the left ventricle subjected 
to LAD ischaemia and reperfusion was analyzed for infarct size by the 
method previously described (Nachlas et al., 1963). Vehicle controls 
received PBS and Sham controls underwent the same surgical manipulation, 
but not LAD ischaemia and reperfusion.  
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Table 5.2.1.1 Experimental Design: Myocardial infarct size and adult 
bone marrow derived mesenchymal stem cells (MSC) therapy upon 
reperfusion  
Group n Reperfusion Protocol  IV Injection upon Reperfusion 
Sham 6 No I/R-2h 0.5 ml PBS 
PBS 8 I/R-2h 0.5 ml PBS 
MSC-0.5 4 I/R-2h 0.5 x106 MSC in 0.5 ml PBS 
MSC-1 5 I/R-2h 1 x106 MSC in 0.5 ml PBS 
MSC-2.5 5 I/R-2h 2.5 x106 MSC in 0.5 ml PBS 
MSC-5 7 I/R-2h 5 x106 MSC in 0.5 ml PBS 
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5.2.2 Results	
In Figure 5.2.2.1 (A) The AAR (% LV) from I/R, was no different 
between the controls and treatment groups. Similarly, in Figure 5.2.2.2, I 
have shown that the haemodynamic parameters mean arterial pressure, heart 
rate and pressure rate index were not different between the controls and 
treatment groups at all time points. When compared with PBS, the injection of 
MSC at reperfusion did attenuate myocardial infarct size and these reductions 
were statistically significant particularly when the number of MSC injected 
were greater than one million cells  (Figure 5.2.2.1 B). 
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Figure 5.2.2.1 Myocardial infarct size and adult bone marrow derived mesenchymal 
stem cells (MSC) therapy upon reperfusion. (A) Area at risk (AAR) from 25 min LAD 
ischaemia and 2 h reperfusion, expressed % LV and was similar between all groups (1-way 
ANOVA, P>0.05). (B) When compared to PBS, infarct size was significantly reduced by a 
single IV bolus of one million or more MSC upon reperfusion (1-way ANOVA and 
Dunnett’s post hoc test, ***P<0.0001). The sham group underwent the same surgical 
procedure but no LAD occlusion. 
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Figure 5.2.2.2 The haemodynamic parameters were similar between all experimental 
groups from baseline to the end of each experiment. (A) Mean arterial pressure (MAP); 
(B) Heart rate (HR); (C) Pressure rate index (PRI) (2-way ANOVA, P > 0.05). 
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5.3 Bone Marrow MSC Therapy and Cardiac 
Function post Regional I/R 
5.3.1 Methods 
Having shown the cardioprotective effect of IV MSC injection at the 
onset of myocardial reperfusion, I then investigated whether MSC injection 
had any effect upon cardiac function. The modalities of transthoracic 
echocardiography and left ventricular pressure catheter quantified indices of 
left ventricular function. Randomly selected Wistar male rats were subjected 
to 25 min of LAD occlusion and reperfusion for 7 days (I/R-7D) as 
described previously (Chapter 2). A delay of 7 days before the acquisition of 
cardiac functional data was necessary to allow for the resolution of post-
ischaemic ventricular stunning (Braunwald and Kloner, 1982). I injected 2.5 
million MSC as a single IV bolus at the onset of reperfusion. After 
thoracotomy closure and 1 hour following the onset of reperfusion the 
general anaesthetic was terminated and animals were recovered. At the end 
of 7 days post I/R-7D, echocardiography and LV pressure catheter data 
acquisition and analysis was undertaken by observers blinded to the 
experimental groups.  
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Table 5.3.1.1 Experimental Design: Myocardial infarct size following 
either IV PBS or bone marrow derived mesenchymal stem cells (MSC) 
in a model of 25 min LAD ischaemia and 7 days reperfusion (I/R-7D). 
Wistar male rats underwent either 25 min LAD occlusion and 7 days of 
reperfusion (I/R-7D) or no LAD occlusion i.e. sham procedure. An IV bolus 
of either PBS or 2.5 million MSC was at the onset of reperfusion. n is the 
number of animals in each group. 
Group n Reperfusion Protocol  IV Injection upon Reperfusion 
Sham 5 No I/R-7D 0.5 ml PBS 
PBS 5 I/R-7D 0.5 ml PBS 
MSC 5 I/R-7D 2.5 x106 MSC in 0.5 ml PBS 
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5.3.2 Results 
In Figure 5.3.2.1, I present the data relating to left ventricular function 
as determined by transthoracic 2D echocardiography, following I/R-7D. 
When compared with controls (PBS), injection of 2.5 million MSC upon 
reperfusion preserved left ventricular function. Thus, both LVEF and FAC 
were significantly higher in the MSC therapy group.  
In Figure 5.3.2.2 (A-E) data for the LV pressure transduction catheter is 
presented. (A-D) when compared with PBS controls, injection of 2.5 million 
MSC upon reperfusion did not significantly improve mean values for 
dP/dtmax, contractility index, dP/dtmin, and tau. (E) However, when compared 
with controls, LVEDP was significantly lower following MSC injection. 
The intraventricular pressure catheter will depend upon LV volume loading 
and the non-significant differences between groups for the dP/dtmax, 
contractility index, dP/dtmin, and tau may have been due to lower LV 
preloading.     
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Figure 5.3.2.1 Transthoracic 2D echocardiography following I/R-7D.(A) Compared to 
PBS, LVEF was significantly higher in animals treated by a single IV bolus of MSC upon  
reperfusion (1-way ANOVA and Dunnett’s post hoc test, ***P<0.0001, n=5). (B) 
Similarly, when compared to the PBS treated animals. Left ventricular fractional area of 
contraction (FAC) was significantly higher for IV injection of MSC injection (1-way 
ANOVA and Dunnett’s post hoc test, ***P<0.0001, n=5). 
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Figure 5.3.2.2 LV pressure catheterisation post I/R-7D. (A) When compared to PBS, 
dP/dtmax was non-significantly higher in animals treated with 2.5 million MSC, upon 
reperfusion. (B) LV contractility index was also non-significantly higher for MSC treated 
animals when compared to the PBS controls.  (C) dP/dtmin was non-significantly lower for 
MSC when compared to the PBS (D) Tau was similar for MSC when compared to PBS. (E) 
Compared to PBS, LV end diastolic pressure (LVEDP) was significantly lower in animals 
treated by MSC upon reperfusion (1-way ANOVA and Dunnett’s post hoc test, P<0.001, 
n=5). 
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5.4 Mesenchymal Stem Cell Therapy and Cardiac 
Fibrosis following Regional I/R	
5.4.1Methods 
A qualitative assessment of the volume of ECM collagen deposition post 25 
min LAD occlusion and reperfusion for 21 days was by picrosirius red 
staining cryosections of Wistar male rat hearts.  The donor 2.5 million MSC 
was by IV bolus at the onset of reperfusion. After 21 days of reperfusion, 
the rats were anaesthetized using 5% isoflurane and then sacrificed by 
cervical dislocation. The hearts were then excised and perfused with 10ml 
of ice cold PBS, followed by 5ml ice cold 4% paraformaldehyde (Sigma) 
via an 18 Ch cannula inserted in the ascending aorta and then immersed for 
30 min in 4% paraformaldehyde on ice. Next the hearts were washed with 
PBS and incubated with 30% sucrose in PBS solution at 4°C overnight. The 
fixed hearts were then cut transversely into two segments between the base 
and the apex. These segments were then embedded in OCT compound 
(VWR) using a polyethylene mould and frozen in liquid nitrogen cooled 
isopentane and stored at -80°C. Cryosections (15-25μm) were cut from each 
segment using a rotary cryotome (Leica) and then placed on polysine-coated 
glass slides (VWR). Cryosections were washed with PBS and dried at room 
temperature overnight. The sections were then immersed in fast blue (0.15% 
Fast Blue in magnesium borate) for 10 min at room temperature. The 
sections were then washed with de-ionised water and stained with 0.1% 
picrosirius red F3B (0.1g Sirus red in 100ml saturated aqueous picric acid) 
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for 10 min at room temperature. The sections were then rinsed in de-ionised 
water for 5 times and then in immersed in picric alcohol (20ml, absolute 
alcohol; 70ml de-ionised water; 10ml saturated aqueous picric acid). 
Sections were then dehydrated through a methanol series and mounted in 
DPX (VWR) and examined by microscopy. 
5.4.2 Results 
 Myocardial fibrosis was demonstrable by increased collagen 
deposition and this was identifiable by increased myocardial uptake of 
picrosirius red (PS). Regions with differential myocardial fibrosis are 
therefore remarkable under microscopic examination. When I compared the 
sham hearts with injection of PBS upon reperfusion, I noted LAD regional 
ischaemia-reperfusion injury and treatment with PBS caused an extensive 
degree of picrosirius red staining within the anterior myocardium of the left 
ventricle. Further, I noted the free wall thickness of the myocardium with 
increased staining with picrosirius red was much thinner, dilated LV cavity, 
and regions remote from increased PS staining were hypertrophied.  In 
contrast, when I compared the picrosirius staining of the PBS treated hearts 
with MSC treated hearts the degree of picrosirius staining was much lower. 
The reduced PS staining was also associated with normal wall thickness and 
a non-dilated left ventricle.  
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Figure 5.4.2.1 Picrosirius red staining. Cryosections of hearts from animals 21 days post 
25 min LAD ischaemia and reperfusion and treated by a single IV bolus of 2.5 million 
culture-expanded mesenchymal stem cells (MSC) or phosphate buffered saline group (PBS) 
upon reperfusion. The sham heart underwent the same surgical procedure except for LAD 
ischaemia and reperfusion. 
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5.5 Discussion 
 In this chapter, I have shown that BM derived MSC could be culture 
expanded to provide non-regenerative stem cell benefits in a rat model of 
regional myocardial I/R. These benefits include the reduction in infarct size 
by 1 million or more MSC given IV upon reperfusion. In concordance with 
the afforded cardioprotection, there was also preservation in myocardial 
function as evidenced by the echocardiogram assessment of ventricular 
function, namely the LVEF and FAC. Although, the LV pressure catheter 
assessment of LV function were not entirely consistent with that noted on 
echo, this may be have been due to lower preloading of LV as suggested by 
the significantly low LVEDP. The benefits of reduction in myocardial 
infarct size and preservation of LV function were also concordant with the 
appearance of significantly reduced ECM fibrosis and absence of adverse 
ventricular remodeling. 
There are particular advantages of using culture expanded MSC as an adult 
stem cell source: 
1. Culture expanded bone marrow MSC might be a potential “off the 
shelf” source of adult stem cells, which would be desirable clinically 
in the emergent treatment of AMI. Clearly, the autologous harvest of 
BMMNC would be time consuming and harvested BMMNC might 
not be available for administration at the onset of coronary 
reperfusion, in a case of AMI. 
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2. That allogeneic MSC injection might be feasible has been suggested 
by data that suggests that MSC are “immune-privileged” and are 
unlikely to cause a host immune reaction (Meisel et al., 2004). 
Further, clinical data from bone marrow transplant patients suggest 
allogeneic and donor mismatch MSC injections are beneficial in 
steroid refractory graft versus host disease (Le Blanc et al., 2008).  
3. Autologous bone marrow MSC might be harvestable and culture 
expanded well in advance of a cardiac procedure where a significant 
period of regional or global myocardial reperfusion injury is 
anticipated, e.g. complex open-heart surgery. 
4.  Autologous bone marrow MSC harvested well in advance might be 
optimised for improved non-regenerative and possibly regenerative 
benefits, e.g. MSC over expressing Akt (Gnecchi et al., 2006).        
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Chapter 6 
Trafficking of Stem Cells during 
Regional Myocardial I/R 
 6.1 Introduction 
 Thus far, I have shown that a single IV bolus of exogenous BM 
derived  stem cells when injected at the onset of reperfusion can attenuate 
myocardial reperfusion injury. There is, however, a vast endogenous stem 
cell reservoir contained within the bone marrow architecture of the entire 
endoskeleton. The mobilisation of bone marrow stem cells is by signaling 
between stromal cell derived factor-1 (SDF-1) and its cognate receptor 
CXCR4. Endothelial and stromal cellular lining of the bone marrow stem 
cell niche constitutively expresses SDF-1, which interacts with its cognate 
receptor CXCR4 expressed on the stem cell surface (Dar et al., 2005; Imai 
et al., 1999; Ponomaryov et al., 2000). Further, signaling between bone 
marrow vascular niches expressing SDF-1 and haematopoietic stem cell 
surface expressed CXCR4 signaling contributes to the retention and 
quiescence of haematopoietic stem cells in their endosteal niches (Nie et al., 
2008). During homeostasis, bone marrow stem cells continually and 
variably egress into the blood stream in a circadian cyclical manner. These 
circadian changes in the levels of circulating bone marrow stem cells is 
under sympathetic control via noradrenaline binding to beta-3-adrenoceptors 
on bone marrow stromal cells to decrease expression of SDF-1 and reduced 
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CXCR4 signaling (Mendez-Ferrer et al., 2008). These daily changes in bone 
marrow stem cell mobilisation are, however, slow and peak 5 h following 
exposure to light (Mendez-Ferrer et al., 2008). In stress or pathological 
states, e.g. following AMI there is an elevation of SDF-1 in the heart, which 
intravasates to create a chemokine or SDF-1 gradient between the bone 
marrow stem cell niche and site of the myocardial infarction for trafficking 
of mobilised stem cells (Askari et al., 2003; Ceradini et al., 2004; Jiang et 
al., 2002; Wojakowski et al., 2004). Taking into account that SDF-1 is 
highly expressed by the bone marrow stem cell niche (Sugiyama et al., 
2006), a rapid and massive intravasation of bone marrow stem cells would 
require a commensurate reduction in SDF-1 activity within the bone marrow 
niche.  The data that I have presented thus far suggests that the endogenous 
bone marrow stem cell mobilisation cannot match the timing and magnitude 
of an exogenous bone marrow stem cell delivery. Direct disruption of 
CXCR4 and SDF-1 interaction, however, can lead to a massive and rapid 
mobilisation of endogenous bone marrow stem cells (Broxmeyer et al., 
2005; Sweeney et al., 2002).  An important endogenous mechanism that 
leads to the direct disruption of CXCR4 and SDF-1 interaction and de-
adhesion of stem cells from their niche is the stem cell expression of CD26. 
CD26 is a type II transmembrane glycoprotein with extra-membranous 
dipeptidyl peptidase-4 activity to cleave and inactivate SDF-1 (Zhai et al., 
2009). Moreover, the reduced expression of CD45 expression leads to 
impairment of SDF-1 function, which can also contribute to a reduction in 
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stem cell retention within the bone marrow (Shivtiel et al., 2008). In this 
chapter, I have investigated modulations in the endogenous bone marrow 
mononuclear cell phenotype in the context of regional myocardial 
ischaemia-reperfusion injury. In chapter 3, I presented data that 
demonstrated equivalent protection by exogenous BMMNC injection and 
ischaemic preconditioning.  Thus, I examined whether myocardial 
ischaemic preconditioning modulated the endogenous bone marrow stem 
cell phenotype, given that it is the most powerful endogenous myocardial 
protective strategy against I/Rinjury, to date (Murry et al., 1986).  
6.2 Modulation of Endogenous BMMNC Phenotype 
post Regional Myocardial I/R 
6.2.1Methods 
 Randomly selected Wistar male rats were subjected to I/R-2h and  
subsequently underwent BM removal from femurs and tibae, as previously 
described (Chapter 2). Sham controls underwent the same surgical 
procedure but no LAD occlusion. BMMNC were isolated from the BM by 
Percoll density gradient centrifugation, as previously described. Primary 
monoclonal antibodies for cell surface markers CD34, CD45, CD133, c-Kit, 
were separately added to one million BMMMC aliquots for 30 min on ice. 
BMMNC were washed twice with 1 ml HBSS, centrifugation (1500 rpm for 
5 min), resuspended in 100 µl HBSS and the secondary antibody incubation 
was added and cell kept for 30 min on ice and washing twice with HBSS (1 
ml). BMMNC were fixed in 2% paraformaldehyde PBS (500 µl) and 
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analyzed by fluorescence activated cell sorting (FACS) flow cytometry 
using a DakoCyan flowcytometer equipped with Summit v4.3 software 
(DakoCytomation, UK). FACS data collected 10,000-gated events using 3-
decade logarithmic amplification.  
6.2.2 Results 
 When compared with sham animals, there was a non-significant 
elevation in the endogenous expression of CD34, CD133 and c-Kit positive 
bone marrow mononuclear cell in animals subjected to 25 min LAD 
ischaemia and 2 h reperfusion (I/R). This modulation in endogenous 
phenotype effect is lower when animals subjected to I/R and receive a single 
IV injection bolus of exogenous 10 million ex vivo unfractionated BMMNC. 
Interestingly, when compared with the shams, animals subjected to I/R had a 
significantly higher expression of the endogenous bone marrow CD45 
positive cells, which was lower in those animals subjected to I/R and 
receiving BMMNC upon of reperfusion. This lowered expression of 
endogenous bone marrow CD45 positive cells by the injection exogenous 
BMMNC upon of reperfusion, however, did not achieve statistical 
significance (Figure 6.2.2.1). Thus in summary, I/R increased the 
endogenous bone marrow expression of CD34, CD133, c-Kit and CD45 
positive mononuclear cells, where only the augmented expression of CD45 
positive cells was statistically significant.  Secondly, the higher endogenous 
bone marrow expression of CD34, CD133, c-Kit and CD45 positive 
mononuclear cells caused by I/R was reducible by the administration of 
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exogenous BMMNC, but these reductions were not statistically significant. 
These results suggest that endogenous bone marrow stem cell phenotype 
changes in response to myocardial I/R injury and that a timely injection of 
exogenous BMMNC may be significantly beneficial to the endogenous bone 
marrow response to myocardial injury.  
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Figure 6.2.2.1 Flow cytometry phenotype analyses for the haematopoietic stem cell 
markers CD34, CD133, CD45 and c-kit of ex vivo endogenous BMMNC. (A, B&C) 
When compared with sham, 25min LAD ischaemia and 2 h reperfusion (I/R) non-
significantly elevated CD34, c-kit and CD133 positive endogenous BMMNC. The increase 
in endogenous CD34, CD133 and c-kit positive cells following I/R was non-significantly 
attenuated by a single IV bolus of 10 million ex vivo unfractionated BMMNC. (D) When 
compared with shams, I/R-2h significantly augmented endogenous BMMNC CD45 
positive phenotype (1-way ANOVA and Dunnett’s post hoc test, P< 0.05, n=10). 
 
Sh
am I/R
I/R
+B
M
M
NC
0
20
40
60
80
100
A
C
D
34
 (%
)
Sh
am I/R
I/R
 + 
BM
M
NC
0
20
40
60
80
100
B
 c
-K
it 
(%
)
Sh
am I/R
I/R
 + 
BM
M
NC
0
20
40
60
80
100
C
 C
D
13
3 
(%
)
Sh
am I/R
I/R
 + 
BM
MN
C
0
20
40
60
80
100 P<0.05
D
C
D
45
 (%
)
 
 
157 
 
6.3 Modulation of Endogenous BMMNC Phenotype 
post Ischaemic Preconditioning and Regional 
Myocardial I/R 
6.3.1 Methods 
 Randomly selected Wistar male rats underwent 2 cycles of 5 min 
LAD ischemia and 5 min of reperfusion for ischaemic preconditioning  
(IPC) of the myocardium. Subsequent to the IPC, animals underwent I/R-2h. 
Sham controls underwent the same surgical procedure but no LAD 
occlusion. At the end of reperfusion, BMMNC were isolated from the BM 
of femurs and tibae, as previously described (Chapter 2). Primary 
monoclonal antibodies for the cell surface markers CD34, CD45, CD133, c-
Kit, CD26, and CXCR4 were separately added to one million BMMMC 
aliquots for 30 min on ice. BMMNC are washed twice with 1ml HBSS, 
centrifugation (1500 rpm for 5 min), resuspended in 100 µl HBSS and the 
secondary antibody incubation was added and cell kept for 30 min on ice 
and washing twice with HBSS (1ml). BMMNC were fixed in 2% 
paraformaldehyde PBS (500 µl)  and analyzed by FACS flow cytometry 
using a DakoCyan flowcytometer equipped with Summit v4.3 software 
(DakoCytomation, UK). FACS data collected 10,000-gated events using 3-
decade logarithmic amplification. 
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6.3.2 Results 
 When compared with sham, animals subjected to IPC followed by 
I/R-2h had a non-significant elevation in the endogenous expression of 
CD34 and c-Kit positive BMMNC. Endogenous BMMNC expression of 
CD133 was similar between groups. Interestingly, when compared with 
sham group, endogenous BMMNC expression of CD45 was significantly 
lower in those animals subjected to IPC followed by I/R-2h (Figure 6.3.2.1). 
Further, when compared to sham animals, following IPC and I/R-2h caused 
endogenous BMMNC to highly express both CD26 and CXCR4; CD26 
expression was at least six folds higher whilst CXCR4 expression was 10 
folds higher (Figure 6.3.2.2) 
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Figure 6.3.2.1 FACS flow cytometry phenotype analyses for the haematopoietic stem 
cell markers CD34, CD133, CD45 and c-Kit in endogenous BMMNC. (A & B) When 
compared with sham, ischaemic preconditioning followed by 25min LAD ischaemia and 2 
h reperfusion (IPC+I/R) non-significantly elevated CD34 and c-kit expression. (C) 
Compared to sham, IPC+I/R had similar expression of CD133 positive endogenous bone 
marrow mononuclear cells. (D) When compared with shams, IPC+I/R significantly 
attenuated the endogenous CD45 positive endogenous bone marrow mononuclear cells 
(unpaired Student’s t test, P< 0.001, n=5). 
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Figure 6.3.2.2 Flow cytometry phenotype analyses for the expression of endogenous 
stem cell trafficking surface markers CD26 CXCR4 in endogenous BMMNC. (A) 
When compared with sham, ischaemic preconditioning (IPC) followed by 25min LAD 
ischaemia and 2 h reperfusion (I/R) significantly augmented CD26 expression in the 
endogenous BMMNC (unpaired Student’s t  test, P< 0.0001, n=5). (B) In concordance, 
compared to sham, IPC+I/R significantly augmented expression of CXCR4 expression in 
the endogenous BMMNC (unpaired Student’s t  test, P< 0.01, n=5). 
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6.4 Discussion 
 In this chapter, I have presented data that demonstrates that the 
endogenous bone marrow derived BMMNC are capable of modulating their 
phenotype in response to the stress of regional myocardial ischaemia and 
reperfusion injury. This data is in concordance with previous data in that it 
suggests that the bone marrow is a dynamic system with an important role 
for the provision of stem cells to the repair of tissue injury (Kollet et al., 
2003). Firstly, I have shown that regional myocardial ischaemia and 
reperfusion caused the bone marrow derived BMMNC expression of CD45 
to increase, which would be in accordance to the rise of inflammatory 
cytokines in the circulation (Lapidot et al., 2002). This augmented BMMNC 
CD45 expression suggests an an inflammatory response by the bone marrow 
following I/R. Thus, the response to regional myocardial ischaemia and 
reperfusion injury is to increase mobilisation of haematopoietic stem cells 
and production of leucocytes. Secondly, I have shown that the injection of 
10 million exogenous bone marrow derived BMMNC caused the 
endogenous bone marrow derived BMMNC to decrease expression of 
CD45. This non-significant but definite trend suggests that the injection of 
exogenous BMMNC acted to reduce the degree of myocardial injury to  
ischaemia and reperfusion and consequently the cross talk between the 
circulating blood and the bone marrow may have been to attenuate the 
inflammatory cellular output from the bone marrow. I do not present data to 
show that the attenuated CD45 positive endogenous bone marrow cells 
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translated to a decreased leukocyte efflux and trafficking to the ischaemic 
regions of the myocardium. Nevertheless, it would be reasonable to assume 
that a significantly reduced inflammatory cellular influx into the ischaemic 
and reperfused myocardium may have contributed, at least in part, to the 
observed attenuation of myocardial injury.  
 Myocardial ischaemic preconditioning followed by 25 min LAD 
ischaemia and 2 h reperfusion altered the endogenous bone marrow 
mononuclear cellular composite phenotype. Interestingly, similar to the 
bone marrow cellular modulation caused by an exogenous BMMNC 
injection, ischaemic preconditioning also caused a reduction in endogenous 
bone marrow expression of CD45 positive mononuclear cells. Ischaemic 
preconditioning, however, caused an approximate three folds reduction in 
CD45 expression, which was statistically significant.  This suggests that the 
crosstalk between preconditioned myocardium and the endogenous bone 
marrow would be to reduce the bone marrow production and subsequent 
discharge of inflammatory cells, whilst augmenting C34 and c-kit positive 
cells. In concordance with the augmented C34 and c-kit positive 
endogenous bone marrow mononuclear cell expression, the communication 
between the preconditioned myocardium also resulted in increased bone 
expression of CD26 that was least six folds greater than that for the sham 
animals. The increase in CD26 expression was also associated with a higher 
expression of CXCR4 that was approximately 10 fold higher than for the 
bone marrow mononuclear cells from sham animals. Stem cell expression of 
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CXCR4 can be rapidly increased by externalization of intracellular stores on 
human CD34 positive cells leading to increased SDF-1 mediated trafficking 
(Kollet et al., 2003; Peled et al., 1999). These findings are in concordance 
with the clinical use of granulocyte colony stimulating factor (G-CSF) for 
mobilization of haematopoietic stem cells by decreasing SDF-1 expression 
and up regulating CXCR4 in human and murine bone marrow (Petit et al., 
2002). Stem cell mobilisation by G-CSF, however, is slow and takes 
approximately 5 days to peak. The magnitude of increased CD26 expression 
would suggest a more direct inhibition of SDF-1 within the bone marrow 
stem cell niche. Direct SDF-1 and CXCR4 disruption would lead to a rapid 
and massive increase in the circulating bone marrow derived stem cells as 
previously documented (Broxmeyer et al., 2005; Sweeney et al., 2002). A 
direct disruption of SDF-1 and CXR4 bonding as suggested by the six-fold 
CD26 expression would be consistent with a massive mobilization of 
endogenous bone marrow stem cells, which could be on par with an 
exogenous bolus injection of BMMNC. This may also explain the parity of 
cardioprotection when comparing ischaemic preconditioning and exogenous 
bone marrow stem cell injections at the onset of reperfusion, as suggested 
by the data I presented in chapter 3.  
Taken together, these findings are concordant with the data that I 
have presented and the data from others reporting the phenomena of 
cardioprotection associated with ischaemic preconditioning, which was 
initially reported by Murry et. al. (Murry et al., 1986).  Thus, the data 
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presented here suggests that the cardioprotection afforded by ischaemic 
preconditioning may have role for highly augmented mobilization of 
endogenous bone marrow derived CD34 and c-kit positive stem cells, which 
may be essential for limiting and reparation of myocardial injury due to 
ischaemia and reperfusion. Moreover, a mechanism of cardioprotection by 
the rapid and massive mobilization of bone marrow derived stem cells might 
also explain the comparable myocardial protection afforded by myocardial 
ischaemic preconditioning, remote ischaemic preconditioning and post-
conditioning.  
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Chapter 7 
 
Mesenchymal Stem Cell Therapy and 
IPC are Synergistic 
 7.1 Introduction 
 In chapter 3, I presented data that suggested that cardioprotection by 
an exogenous bone marrow derived stem cell injection is comparable to 
myocardial ischaemic preconditioning. In the previous chapter, I have 
presented further data that suggests that myocardial ischaemic 
preconditioning may have a role in the swift and massive mobilization of 
endogenous bone marrow derived haematopoietic stem cells.  The exact 
mechanism for cardioprotection afforded by ischaemic preconditioning is 
not entirely clear in the literature, despite its discovery more than 25 years 
ago (Murry et al., 1986). A recent review by Yellon et. al., had suggested 
that the molecular mechanism underlying ischaemic preconditioning might 
be due to the activation of survival kinase signaling (Yellon et al., 2007). In 
conjunction with the data presented in chapter 4, which suggests that the 
exogenous injection of bone marrow derived stem cells activate PI3K/Akt 
survival kinase pathway. I hypothesized that the underlying mechanisms for 
cardioprotection afforded by both exogenous bone marrow stem cell therapy 
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and ischaemic preconditioning are reliant upon a massive deployment of 
bone marrow derived stem cells within the systemic circulation. I tested this 
hypothesis by investigating whether the cardioprotection afforded by 
ischaemic preconditioning might augment the cardioprotection afforded by 
exogenous bone marrow derived MSC injection at the onset of reperfusion, 
in an anaesthetised Wistar male rat model of regional myocardial ischaemia 
and reperfusion. 
7.2 IPC plus Mesenchymal Stem Cell Therapy and 
Infarct Size post Regional Myocardial I/R 
7.2.1Methods 
 Randomly selected Wistar male rats underwent 25 min LAD 
ischaemia and 2 h reperfusion. Donor MSCs were isolated from BM 
obtained from ex vivo femurs and tibae of Wistar male rats, as described 
previously (Chapter 2). The isolated and culture expanded cells were 
phenotyped by FACS flow cytometry for   CD34, CD133, CD45, c-Kit, 
CD29, and CD90 as previously described (Chapter 2). Following culture 
expansion, cells were mobilised by removal of culture media and 
deadhesion with 5 ml 0.25% trypsin-EDTA for 5 min in a 37oC incubator 
with 5% CO2. The disassociated cells are collected in 1ml Hank's Buffered 
Salt Solution, centrifuged 1500 rpm for 5 min, and resuspended in 0.5 ml 
PBS. Randomly selected syngeneic Wistar male rats were subjected to 25 
min LAD occlusion and 2 h of reperfusion (I/R-2h). At the onset of 
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reperfusion, MSC therapy animals received 2.5 million MSC by IV bolus 
injection. At the end of 2 h reperfusion, the region of the left ventricle 
subjected to I/R-2h was analyzed for myocardial infarct size, as previously 
described. The controls received PBS and Sham animals underwent the 
same surgical manipulation as the other animals except for LAD occlusion 
and reperfusion. 
  
7.2.2 Results 
 With reference to figure 7.2.2.1, the comparison of the sham animal 
group with the animals receiving PBS at reperfusion demonstrated a 
significantly increased left ventricular infarct size (Sham: 7± 0.9% versus 
PBS: 55 ± 2%, P< 0.0001, n = 9). Conversely, when comparing the PBS 
group with the animals that were subjected to IPC, there was a significant 
reduction in left ventricular infarct size (PBS: 55± 2%, versus IPC:30 ± 3% 
P< 0.0001, n = 6). The injection of 2.5 million exogenous MSCs at the onset 
of reperfusion consistently reduced left ventricular infarct size as compared 
to the PBS controls (PBS: 55± 2%, versus MSC: 25 ± 5% P< 0.0001, n = 5). 
Interestingly, when compared with the PBS controls, animals that had 
received 2.5 million cells pre-ischaemia and a further 2.5 million MSC at 
the onset of reperfusion (MSC+MSC) also had a significant reduction in left 
ventricular infarction, but this was similar to that in animals receiving MSC 
only upon reperfsuion. Thus, there was, however, no additional benefit 
conferred by the extra injection of 2.5 million MSC prior to the onset of 
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ischaemia (PBS: 55± 2%, versus MSC+MSC: 23 ± 10% P< 0.0001, n = 5). 
As hypothesized, when I compared PBS controls with animals that 
underwent IPC and then received 2.5 million exogenous MSC at the onset 
of reperfusion (IPC+MSC), there was a dramatic reduction in left 
ventricular myocardial infarction, similar to that in the sham animal group 
(PBS: 55± 2%, versus IPC+MSC: 6 ± 2% P< 0.0001, n = 7). There were no 
significant differences in the left ventricular area at risk between the 
controls and the treatment groups. There were also no demonstrable 
difference in the haemodynamic parameters between the controls and 
treatment groups (Figure 7.2.2.2). 
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Figure 7.2.2.1 (A) The area at risk (AAR) from 25 min LAD ischaemia and 2 h LAD 
reperfusion, expressed as % LV was similar between all groups (1-way ANOVA, P>0.05). 
(B) When compared with controls (PBS), IPC, pre-treatment with an IV bolus of 2.5 
million MSC and then a further IV bolus of 2.5 million MSC upon reperfusion 
(MSC+MSC), and IPC+MSC upon reperfusion significantly attenuated infarct size (1-way 
ANOVA and Dunnett’s post hoc test, ***P<0.001, n=5). When comparing IPC with 
IPC+MSC, there was a further significant reduction in infarct size beyond that by IPC alone 
(P<0.01, n=7). The sham group underwent the same surgical procedure except for LAD 
ischaemia and reperfusion.  
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Figure 7.2.2.2 (A) MAP was significantly higher at reperfusion times: 60min for 
MSC+MSC, 90min and 120min for IPC+MSC group.  (B) Compared to PBS, HR was 
significantly lower in shams at ischaemia times 0, 5, 15 and 25min. (C) PRI were similar 
between all experimental groups from baseline to the end of each experiment (2-way 
ANOVA and Bonferonni’s post hoc test, P > 0.05). Sham group under the same surgical 
procedure except for I/R. 
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7.3 Discussion 
 In this chapter, I have presented data that  tested the hypothesis that 
cardioprotection afforded by either ischaemic preconditioning or exogenous 
bone marrow derived stem cell therapy is reliant upon a swift and massive 
mobilization of stem cells into the peripheral circulation.  I have presented 
data where the combination of IPC with the systemic injection of exogenous 
bone marrow derived MSCs upon reperfusion reduced myocardial infarct 
size to sham levels. The magnitude of cardioprotection afforded suggests 
that the two cardioprotective strategies were acting in synergy. These data 
also suggest the injection of 2.5 million exogenous MSC prior to the onset 
of reperfusion did not have any additional benefit to that afforded by the 
timely injection at the onset of reperfusion. The reason why this may be so 
is that a lack of SDF-1 expression by the myocardium prior to the onset of 
ischaemia may have lead to the exogenous MSC trafficking to tissues with 
the higher constitutive expression of SDF-1 such as the bone marrow or the 
spleen. It thus follows, that the haematopoietic stem cells mobilized by 
ischaemic preconditioning and the injected MSC may have trafficked to a  
high SDF-1 gradient created by the ischaemic myocardium.  
IPC is the phenomenon attributable to the diligent study by Murry, 
Jennings and Reimer in 1986 and since its initial description it has become 
one of the most quoted scientific studies in the cardiovascular literature 
(Murry et al., 1986). The following data from this landmark study 
corroborate the data that I have presented in this and the previous chapter.  
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(1) Murry et. al., reported that preconditioning the heart was only 
cardioprotective in the short or 40 min ischaemia model but not in the 3 h 
ischaemia model. When taken together with my data, it suggests that the 
bone marrow derived stem cells were mobilised into the circulation by 
ischaemic preconditioning. However, in the absence of reperfusion within 
the first 2 h or so and in the absence of an SDF-1 chemokine gradient, the 
mobilized stem cells would have trafficked back to the bone marrow. 
Hence, the lack of protection observed in the 3 h ischaemia model. (2) The 
pattern of injury described in the 40-minute ischaemia model is patchy and 
diffuse, which is consistent with the pattern of exogenous stem cell 
engraftment into the myocardium following IV injection, which is 
consistent with observations in my laboratory and that by others. In contrast, 
the pattern of injury in the 40 min controls and 3h ischaemia model had 
solid or confluent infarcts.   (3) Murry et. al., also report that pre-treatment 
with verapamil in the 40 min ischaemia and reperfusion model was 
significantly cardioprotective, but continuous verapamil initiated 15 min 
after the onset of ischaemia in the 3 h ischaemia model was not 
cardioprotective. Following this observation, the authors suggest that 
verapamil pre-treatment might share a common mechanism with IPC. 
Interestingly, a more recent report suggests that verapamil can disrupt the 
SDF-1/CXCR4 signaling axis in bone marrow derived stem cells and impair 
in vitro MSC migration (Wang et al., 2008). Thus, pre-treatment with 
verapamil may lead to stem cell mobilization from the bone marrow; 
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however, continuous verapamil injection could impair stem cell trafficking 
to the ischaemic myocardium. Indeed, blocking the CXCR4 receptor 
disrupts the SDF-1/CXCR4 cell-cell adhesion but the mobilized cells cannot 
home to tissues highly expressing SDF-1, such as lung, liver and bone 
marrow (Burger et al., 2009; Liang et al., 2004). 
 Following the description of myocardial IPC, there have been 
consistent reports of preconditioning the heart in numerous ex vivo and in 
vivo experimental models and clinical scenarios. In fact, preconditioning the 
myocardium can be by pharmacological and non-pharmacological stimuli 
that not necessarily require an initial ischaemic myocardial event. More 
recently, the phenomenon of remote preconditioning where the ischaemic 
event is distant to the target organ has been reported.    
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Chapter 8 
8.1 General Discussion  
Adult stem cell therapy to regenerate myocardial infarction thus far 
remains a clinical non-entity despite the passage of more than a decade 
since the promise of the earliest experimental reports. Whether this potential 
benefit of adult stem cell therapy becomes a reality of future clinical 
practice remains uncertain. In the course of this thesis, I have investigated 
another potential use of adult stem cell therapy namely the  non-regenerative 
benefits of adult bone marrow derived stem cell therapy in a rat model of 
acute myocardial ischaemia and reperfusion. The initial work demonstrated 
that unfractionated BMMNC when applied as early as the onset of 
reperfusion can powerfully attenuate acute myocardial infarction, preserve 
myocardial function, and prevent adverse ventricular remodeling. This 
degree of myocardial protection was similar to that afforded by IPC, which 
is the undisputed gold standard for myocardial protection.  
The initial experiments investigated whether infarct size could be 
attenuated by adult bone marrow derived stem cells or BMMNC therapy. 
The unfractionated BMMNC were phenotypically positive for the surface 
markers CD34, CD133, c-Kit, which are typically expressed by bone 
marrow haematopoietic stem cells. Donor BMMNC cell counts were high 
for CD45 phenotype, which is a pan leukocyte marker used to identify T or 
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B-lymphocytes within the haematopoietic progenitors. This might appear to 
be counter-intuitive for myocardial protection, considering that the injected 
CD45 positive cell population could differentiate into inflammatory 
macrophages and exacerbate I/R injury. In contrast, BMMNC injection 
afforded myocardial protection, this  suggesting that  lineage differentiation 
of donor BMMNC into an inflammatory cells was unlikely during acute 
reperfusion. Although at this stage I could not  entirely dismiss BMMNC 
transdifferentiation into de novo myocardium there were, however, a 
number of aspects that did not support BMMNC differentiation to be the 
principal mechanism responsible for myocardial protection. Firstly, the 
injected BMMNC had not been enriched for c-Kit postive BMMNC, which 
was considered to be necessary in the initial myocardial regeneration studies 
using adult bone marrow derived BMMNC as reported by Orlic et. al., and 
Jackson et. al.,(Jackson et al., 2001; Orlic et al., 2001).  Secondly, the length 
of time following cell injection and the observed benefit at the 2 h endpoint 
could not support BMMNC differentiation into functional cardiomyocytes 
as the primary mechanism for infarct size reduction. Orlic et. al., reported 
regeneration of myocardium 9 days post cell injection and currently there is 
no data to suggest that adult stem cells can differentiate into fully functional 
cardiomyocytes within 2 hours of cell delivery. Thirdly, the number of adult 
stem cells retained in the ischaemic myocardium following intravenous 
injection is suggested to be very small in comparsion to that accumulating in 
the liver, lungs, kidneys and spleen (Aicher et al., 2003; Barbash et al., 
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2003). Lastly, the initial experimental data corroborated that which had been 
reported by Murry et al., and Balsam et al., suggesting that donor BMMNC 
do not undergo differentiation into any of the cell types of myocardial 
lineage (Balsam et al., 2004; Murry et al., 2004).   
Therefore, I then turned my focus to the non-regenerative aspects of adult 
bone marrow derived stem cell therapy. In contrast to differentiated cells, adult and 
embryonic stem cells highly express cytoprotective genes associated with 
resistance to oxidative stress, repair of DNA, and detoxifier systems (Dernbach et 
al., 2004; Ivanova et al., 2002; Ramalho-Santos et al., 2002). Proteomics of stem 
cell also suggest that these cytoprotective genes are highly translated (Feldmann et 
al., 2005).These essential cytoprotective mechanisms ensure bone marrow stem 
cell survival within their relatively hypoxic stem cell niche (Uccelli et al., 2008; 
Wilson et al., 2006). The next stage of my thesis was to elucidate the nature 
of BMMNC non-regenerative mechanisms and their role in attenuating 
acute ischaemia and reperfusion. By isolating the cardiomyocytes from the 
region of the myocardium subjected to ischaemia and reperfusion, I was 
able to show that BMMNC therapy attenuated cardiomyocyte death by 
reducing both cardiomyocyte apoptosis and necrosis. This attenuation of 
cardiomyocyte apoptosis and necrosis was most effective when BMMNC 
therapy was initiated at the onset of myocardial reperfusion. This 
observation was concordant with both the myocardial infarction data 
presented in chapter 3 and also with suggested homing mechanism of bone 
marrow stem cells i.e at the peak of the myocardial expression of SDF-1, 
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which is at the end of ischaemia (Askari et al., 2003; Ceradini et al., 2004; 
Jiang et al., 2002; Wojakowski et al., 2004).  
Having suggested that BMMNC therapy afforded protection by non-
regenerative means, I tested whether adult stem cell secreted factors could 
mediate cardioprotection in lieu of the cell injection. Interestingly, I found 
that removing the cells from BMMNC therapy did not eliminate 
cardioprotection. The BMMNC derived paracrine factors were, however,  
required to be highly concentrated such that BMS derived from at least 20 
million BMMNC over at least 24 hours was necessay to replicate the 
cardioprotection that was afforded by 10 million BMMNC, which could be 
injected immediately following isolation. These data supported BMMNC 
mediated cardioprotection was (1) non-regenerative (2) dependent upon the 
trafficking of stem cells, possibly by SDF-1/CXCR4 signaling, to the 
ischaemic and myocardium.  
In order to further understand the molecular mechanisms undelying 
BMMNC derived paracrine factors, I conducted a proteomic analysis of the 
left ventricular region that had been subjected to I/R-2h and treated with 
either BMMNC or BMS. The comparison of the LV proteome of hearts 
treated with either 10 million BMMNC or BMS, from 50 million BMMNC 
over 24 hours, suggested that a number of proteins might have a role in 
BMMNC mediated cardioprotection. Proteomic data suggested BMMNC 
were cardioprotective by a wide number of survival mechanims as 
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suggested by differential protein expression of (a) anti-apoptotic signal 
transduction protein 14-3-3 epsilon (b) anti-oxidants (c) heat shock proteins 
(d) glycolytic proteins (e) mitochondrial respiratory proteins.  
The higher expression of 14-3-3 epsilon was equally up-regulated 
following either BMMNC or BMS therapy. An augmented expression of 
14-3-3 epsilon was concordant with anti-apoptotic effects of BMMNC 
therapy (chapter 4) and suggested PI3K/Akt survival kinase signaling may 
have a major role for BMMNC mediated cardioprotection. That this was 
indeed the case was also suggested by the augmented phosphorylation of 
Akt by BMMNC therapy, as noted in the Western blots. That the 
downstream phosphorylation of GSK-3beta of the PI3K/Akt survival kinase 
signaling suggested that BMMNC therapy could have inhibited 
mitochondrial MPTP opening during reperfusion. Prevention of MPTP 
opening by BMMNC therapy was also suggested by the significantly higher 
expression of the mitochondrial VDAC-1.  
Proteomic study of BMMNC therapy mediated cardioprotection also 
suggested that BMMNC therapy caused  higher expression of anti-oxidants 
(Table 4.4.4). In connection with this, the activation of  p38 MAPK during 
I/R is suggested to be causally linked to increased ROS, particularly H2O2 
(Meldrum et al., 1998). Activation of  p38 MAPK during I/R can augment 
myocardial I/R injury (Chai et al., 2008; Gao et al., 2002; Jaswal et al., 
2007; Kumar et al., 2004). Active p38 MAPK is suggested to augment I/R 
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by increasing myocardial inflammatory cytokines (Oto et al., 2009; Yin et 
al., 2008). Others, however, suggest the contrary (Steenbergen 2002). In 
concordance with the former, Western blotting suggested that BMMNC 
therapy  attenuated phophorylation of p38 MAPK and also reduced the 
nuclear translocation of the pro-inflammatory cytokine transcription factor 
NF-κB.  
Proteomics also eluded to other cardioprotective benefits associated with 
BMMNC therapy such as a higher expression of heat shock proteins, 
glycolytic proteins, and mitochonrial respiratory proteins. It is of course 
unclear as to which molecular mechanism has the principal role in BMMNC 
cardioprotection and future work might identify BMMNC secreted 
paracrine factors tp help elucidate the principal cardioprotective molecular 
mechanism(s).  
BMMNC therapy in clincal applications where myocardial I/R is 
obligatory such as  heart transplantation, cardiopulmonary bypass, and 
coronary angioplasty might be hampered by the availability of BMMNC for 
immediate injection upon reperfusion. Further, the injection of autologous 
BMMNC i.e. from patients with heart disease and other multisystem co-
morbities may not provide the same therapeutic benefits demonstrated by 
the data presented in this thesis. Importantly, I have used freshly isolated 
syngeneic BMMNC, which were not be available as an “off the shelf” 
option for immediate injection when required. Thus, a clinically feasible 
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adult stem cell therapy would require a stem source that is easily available 
and without excessive delay. Therefore, I investigated whether the other 
major bone marrow stem cell type MSC might be cardioprotective in the 
myocardial I/R-2h rat model. The reasons for this were two fold (1) MSC 
are very easily isolated from whole BM and expanded in culture (2) the 
potential of MSC for allogeneic transplantation. These properties of MSC 
provides potential for MSC banking from healthy donors, for later clinical 
therapy in unrelated recipients. MSCs isolated from ex vivo whole marrow 
were expanded in culture and noted to be CD45 negative, CD29 positive 
and CD90 positive. I have shown that systemic IV injection of MSC at the 
onset of reperfusion could also powerfully attenuate myocardial infarction, 
preserve myocardial function, and prevent adverse ventricular remodeling. 
This suggested that an “off the shelf” BM derived stem cell for potential 
clinical use might be a possibility.  
At this stage of my thesis, I was intrigued that the exogenous 
delivery of two different bone marrow derived stem cell types was 
powerfully cardioprotective but the endogenous bone marrow reservoir of 
the same stem cells types could not afford significant cardioprotection. 
Shintani et al., had, interestingly, reported an increased mobilisation of 
endogenous bone marrow derived stem cells following AMI (Shintani et al., 
2001). This was possibly due to the ischaemia augmented expression of 
myocardial SDF-1 and CXCR4 mediated trafficking of cells from the bone 
marrow niche(Askari et al., 2003; Dar et al., 2005; Sugiyama et al., 2006). 
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However, despite the SDF-1/CXCR4 signaling the  endogenous bone 
marrow stem cell mobilisation during I/R the consequential cardioprotection 
is  insignificant compared to the cardioprotection afforded by exogenous 
stem cell therapy.  
Initial data presented in this thesis suggested that cardioprotection by 
exogenous BMMNC therapy was similar to that afforded by IPC. IPC is the 
phenomenon attributable to the landmark study by Murry, Jennings and 
Reimer in 1986 and since its initial description it has become one of the 
most quoted scientific studies in the cardiovascular literature (Murry et al., 
1986). Further interpretation of this report in the context of the data 
presented in this thesis was interesting in a number of  ways: (1) Murry et. 
al., reported that preconditioning the heart was only cardioprotective in the 
short or 40 min ischaemia model but not in the 3h ischaemia model. When 
taken together with my data, this suggersted that the bone marrow derived 
stem cells could be mobilised by IPC but in the absence of reperfusion or in 
the absence of an SDF-1 chemokine gradient the mobilized stem cells would 
not be able reach the ischaemic myocardium. (2) The pattern of injury 
described in the 40 min ischaemia model is patchy and diffuse, which is 
consistent with the pattern of exogenous stem cell engraftment into the 
myocardium following IV injection. In contrast, the pattern of injury in the 
3 h ischaemia model was solid or confluent infarcts. (3) Murry et. al., also 
reported that pre-treatment with verapamil in the 40 min ischaemia and 
reperfusion model was significantly cardioprotective, but continuous 
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verapamil initiated 15 min after the onset of ischaemia in the 3 h ischaemia 
model was not cardioprotective. Following this observation, the authors 
suggest that verapamil pre-treatment might share a common mechanism 
with ischaemia pre-conditioning. Interestingly, a more recent report 
suggests that verapamil can disrupt the SDF-1/CXCR4 signaling axis in 
bone marrow derived stem cells and impair in vitro MSC migration (Wang 
et al., 2008). Thus, pre-treatment with verapamil may lead to stem cell 
mobilization from the bone marrow; however, continuous verapamil 
injection could impair stem cell engraftment into the ischaemic 
myocardium. Indeed, blocking the CXCR4 receptor disrupts the SDF-
1/CXCR4 signaling and the mobilized cells would therefore not home and 
engraft into tissues highly expressing SDF-1, such as the ischaemic 
myocardium (Liang et al., 2004).  
Having suggested that IPC may have a role in endogenous stem cell 
mobilisation led to experiments where the impact of I/R and IPC upon the 
endogenous BMMNC phenotype and SDF-1/CXCR4 signaling was 
investigated. Firstly, it was notable that I/R augmented endogenous 
BMMNC expression of CD45, which would be in keeping with the rise of 
inflammatory cytokines in the circulation following acute myocardial 
infarction (Lapidot et al., 2002). This augmented endogenous stem cell 
CD45 expression suggests that the initial bone marrow response to regional 
myocardial I/R is to increase mobilisation and production of inflammatory 
leucocytes. In contrast, IPC and I/R had attenuated endogenous BMMNC 
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CD45 positive cells by three folds.  This suggested that the preconditioned 
myocardium attenuated bone marrow  derived inflammatory leucocytes, 
which is concordant with IPC mediated attenuation of myocardial acute 
inflammation. Moreover, endogenous BMMNC attenuated CD45 
expression can impair SDF-1/CXCR4 signaling to reduce endogenous stem 
cell retention within the bone marrow niche (Shivtiel et al., 2008). Direct 
disruption of CXCR4 and SDF-1 interaction, however, can lead to a massive 
and rapid mobilisation of endogenous bone marrow stem cells (Broxmeyer 
et al., 2005; Sweeney et al., 2002). An important endogenous mechanism 
that leads to the direct disruption of CXCR4 and SDF-1 interaction and de-
adhesion of stem cells from their niche is the stem cell expression of CD26. 
CD26 is a type II transmembrane glycoprotein with extra-membranous 
dipeptidyl peptidase-4 activity to cleave and inactivate SDF-1 (Zhai et al., 
2009). In concordance with IPC having a role in increased bone marrow 
stem cell mobilisation, IPC augmented endogenous BMMNC expression of 
CD26 by six folds greater than that for the sham animals. The augmented 
BMMNC CD26 expression was also associated with a higher expression of 
CXCR4 that was approximately 10 fold higher than that for the endogenous 
BMMNC from sham animals. Stem cell expression of CXCR4 can be 
rapidly increased by externalization of intracellular stores on human CD34 
positive stem cells leading to increased plasma SDF-1 mediated trafficking 
(Kollet et al., 2003; Peled et al., 1999). These findings were also in 
concordance with the clinical use of granulocyte colony stimulating factor 
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(G-CSF) for mobilization of haematopoietic stem cells by decreasing SDF-1 
expression and up regulating CXCR4 expression in both human and murine 
bone marrow (Petit et al., 2002). The magnitude of increased CD26 
expression would suggest a more direct inhibition of SDF-1 within the bone 
marrow stem cell niche. Direct disruption of SDF-1 and CXR4 bonding by 
the augmented CD26 and CXCR4 expression would be consistent with a 
massive mobilization of endogenous bone marrow stem cells by IPC.  
Hence the final experiment of the thesis whereby I demonstrated that 
IPC and exogenous MSC injection at the onset of reperfusion could 
synergistically abolish myocardial I/R injury. Further, it is also notable that 
the injection of 2.5 million exogenous MSC prior to the onset of 25 min 
regional ischaemia did not have any additional benefit to that afforded by 
the timely injection of MSC at the onset of reperfusion. This could be 
attributable due to a lack of SDF-1 expression by the myocardium prior to 
the onset of ischaemia and failure of the exogenous  MSC to home into the 
myocardium. The augmented mobilization of endogenous bone marrow 
derived stem cells by IP might be an essential mechanism for limiting 
myocardial I/R injury. Further, the rapid and massive mobilization of bone 
marrow derived stem cells by IP might also explain the comparable 
myocardial protection afforded by remote ischaemic preconditioning and 
post-conditioning.  
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The data presented in this thesis is limited in the following ways: (1) 
there is no data to confirm that the combined effect of IPC and MSC did 
lead to increased exogenous and endogenous stem cell homing and 
engraftment within the ischaemic myocardium. (2) There is no molecular 
data to support the observed enhanced cardioprotection by IPC and MSC 
therapy. (3) The ischaemia time is short and whether the augmented 
protection by IP plus MSC therapy following longer ischaemia times 
persists is debatable.   
Future experimental work should examine whether exogenous bone 
marrow derived stem cell therapy is also cardioprotective in a large animal 
model of myocardial ischaemia and reperfusion injury e.g. the porcine 
model.  Subject to large animal data, this method of cardioprotection might 
be translatable into clinically where myocardial ischaemia and reperfusion is 
obligatory such as heart transplantation, cardiopulmonary bypass and 
coronary angioplasty.  
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